X-linked Dilated Cardiomyopathy

Mendelian MONDO:0010542 Pathograph 23 Show in embeddings browser Dilated Cardiomyopathy Dystrophinopathy

The cardiac-selective dystrophinopathy. XLDCM is caused by mutations in DMD - the same gene as Duchenne and Becker muscular dystrophy - but expressed almost exclusively as dilated cardiomyopathy, with minimal or absent skeletal myopathy. What makes it a distinct entry rather than "the heart part of Duchenne" is where in the gene the lesion falls and how tissue-specific dystrophin promoters respond to it. The paradigmatic lesion is a deletion of the muscle (M) promoter and first muscle exon at the 5' end of DMD. This abolishes the muscle dystrophin isoform (Dp427m) everywhere it is normally made, but skeletal muscle rescues itself by up-regulating the brain (B) and Purkinje (P) isoforms from intact downstream promoters. The ventricular myocardium cannot: the B isoform is expressed in human heart only in the atria and conduction tissue, not in the ventricles, so there is no compensatory transcript available where it matters. The result is a loss of dystrophin that is functionally confined to the ventricle - the direct molecular explanation for a dystrophinopathy that devastates the heart while sparing the limbs. The clinical shape follows the molecular one and is starkly sex-dependent. Hemizygous males present in adolescence or the early twenties with rapidly progressive heart failure and ventricular arrhythmia; in the original kindred, affected males died within 5 to 12 months of symptom onset. Heterozygous carrier females are not unaffected - they develop a milder, later-onset dilated cardiomyopathy in the fourth to fifth decade, its severity tracking skewed X-inactivation. Because there is little or no skeletal weakness to raise suspicion, XLDCM is readily mistaken for idiopathic dilated cardiomyopathy, and DMD defects account for a small but real fraction of young-adult male DCM.

Ask OpenScientist

Ask a research question about X-linked Dilated Cardiomyopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
2
Histopath.
7
Phenotypes
1
Gaps
23
Pathograph
1
Genes
5
Medical Actions
2
Subtypes
3
Models
18
References
1
Deep Research
🏷

Classifications

Harrison's Part
CARDIOVASCULAR GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
X-linked recessive HP:0001419
Hemizygous males are affected early and severely; heterozygous carrier females develop a milder, later-onset dilated cardiomyopathy, and there is no male-to-male transmission - the pedigree signature that distinguishes XLDCM from autosomal dominant familial DCM. Manifesting carriers are common, with expressivity governed by skewed X-inactivation.
X-linked recessive inheritance
Show evidence (2 references)
PMID:3574369 SUPPORT Human Clinical
"X-linked inheritance of dilated cardiomyopathy is suggested in this family by the early onset in males, late onset in females, and no evidence of male-to-male transmission."
The original pedigree evidence for X-linked inheritance, including the no-male-to-male-transmission clue.
PMID:3574369 SUPPORT Human Clinical
"The late onset of the disease in females, in contrast to the early onset in hemizygous males, is compatible with heterozygosity for the mutant allele."
The manifesting-carrier pattern: later-onset disease in heterozygous females.
◆

Subtypes

2
5' muscle-promoter / exon-1 XLDCM
DMD hgnc:2928 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in DMD (hgnc:2928). hgnc:2928 is a gene from the HUGO Gene Nomenclature Committee.
The paradigmatic, severe class: a deletion of the muscle (M) promoter and first muscle exon at the 5' end of DMD abolishes the muscle dystrophin isoform. Skeletal muscle is rescued by up-regulating the brain isoform, but the ventricle cannot, so the phenotype is a rapidly progressive, often lethal cardiomyopathy in adolescent and young-adult males. Standard multi-exon deletion panels can under-detect the isolated promoter-region lesion.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"the causative mutation would include a deletion in the region and in exon 1"
Documents the 5' muscle-promoter/exon-1 deletion that defines this subtype.
Exon 45-55 in-frame deletion XLDCM
DMD hgnc:2928 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in DMD (hgnc:2928). hgnc:2928 is a gene from the HUGO Gene Nomenclature Committee.
An in-frame deletion in the exon 45-55 hotspot presents cardiac-predominantly with mild or absent skeletal disease, a more indolent course, and better responsiveness to ACE-inhibitor/beta-blocker therapy than the 5' class. Serum CK is frequently normal in this subtype.
Show evidence (1 reference)
PMID:18261911 SUPPORT Human Clinical
"Two younger patients diagnosed as having X-linked dilated cardiomyopathy (XLDCM) developed congestive heart failure without overt skeletal myopathy."
Documents the exon 45-55 in-frame deletion class producing cardiac-predominant XLDCM without skeletal myopathy.
?

Discussions and Knowledge Gaps

1
Does any available model reproduce the ventricle-selective, skeletal-sparing dystrophin loss that defines XLDCM, or do all models capture only the combined skeletal-plus-cardiac dystrophinopathy?
HUMAN MODEL MISMATCH OPEN xldcm_cardiac_selective_model_gap
Attached to
pathophysiology#Ventricle-Selective Loss of Dystrophin
The node that makes XLDCM a distinct entity is the ventricle-selective loss of dystrophin driven by failed brain-isoform compensation in the human ventricle. Existing models do not reproduce this selectivity: standard mdx mice show only a mild, late cardiac phenotype; enhanced backgrounds (Cmah-null) and large-animal canine models accelerate or better match the course but carry combined skeletal-plus-cardiac dystrophin loss. The isoform-topography mechanism therefore rests on human autopsy/explant tissue (Neri 2012), and translational validity of model-derived cardiac findings to the cardiac-selective human phenotype remains the open question - so cross-model agreement should be judged mechanism by mechanism rather than treating a mild or combined-phenotype model as representative.
Proposed experiments
Engineered ventricle-selective 5' DMD-isoform model with human-relevant isoform readouts
exp_xldcm_ventricle_selective_model
Build a model (e.g., human iPSC-derived ventricular cardiomyocytes or an animal line) carrying the 5' muscle-promoter/exon-1 lesion, and measure brain- versus muscle-isoform dystrophin transcripts and ventricular dysfunction, testing whether the human isoform-compensation-failure mechanism is reproduced in ventricle without skeletal rescue confounders.
Show evidence (1 reference)
PMID:30281092 SUPPORT Model Organism
"Several mouse models have been developed to study molecular and pathological consequences of dystrophin deficiency, but do not recapitulate all aspects of human disease pathology and exhibit a mild cardiac phenotype."
Direct evidence that standard mouse models under-represent the human cardiac phenotype, the mismatch this discussion records.
⚙

Pathophysiology

9
5' DMD Muscle-Promoter/Isoform-Disrupting Lesion
The initiating lesion. The paradigmatic XLDCM mutation deletes the muscle (M) promoter and first muscle exon at the 5' end of DMD, abolishing transcription of the muscle dystrophin isoform (Dp427m); other XLDCM lesions include in-frame exon 45-55 deletions and destabilizing missense variants. Towbin's linkage study localized the disorder to the centromeric half of the dystrophin locus at Xp21 and showed that cardiac dystrophin was abnormal on Western blot while skeletal-muscle dystrophin was normal - the biochemical signature of a heart-preferential dystrophin defect.
dystrophin actin filament binding GO:0051015 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves dystrophin actin filament binding, annotated with actin filament binding (GO:0051015), qualified as loss of function. GO:0051015 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Downstream
Ventricle-Selective Loss of Dystrophin Abolishing the muscle isoform sets up a tissue-specific failure of compensation that is resolved at the next node.
Show evidence (2 references)
PMID:8504498 SUPPORT Human Clinical
"Linkage of XLCM to the centromeric portion of the dystrophin or Duchenne muscular dystrophy (DMD) locus at Xp21 was demonstrated with combined maximum logarithm of the scores of +4.33"
Establishes DMD at Xp21 as the disease locus, the founding molecular evidence that XLDCM is a dystrophinopathy.
PMID:8504498 SUPPORT Human Clinical
"Abnormalities of cardiac dystrophin were shown by Western blotting with N-terminal dystrophin antibody, whereas skeletal muscle dystrophin was normal, suggesting primary involvement of the DMD gene with preferential involvement of cardiac muscle."
The heart-selective biochemical defect that defines the entity: abnormal cardiac dystrophin against normal skeletal-muscle dystrophin.
Ventricle-Selective Loss of Dystrophin
The node on which the whole entry turns, and the reason XLDCM is cardiac-selective rather than a systemic dystrophinopathy. When the 5' mutation abolishes the muscle (M) dystrophin isoform, skeletal muscle compensates by up-regulating the brain (B) isoform from an intact downstream promoter. The ventricular myocardium cannot: in the healthy human heart the B isoform is expressed only in atrial cardiomyocytes and conduction tissue, and is absent from the ventricles, which transcribe the M isoform alone. With no compensatory transcript available, the ventricle is left dystrophin-deficient while the limbs are rescued.
ventricular cardiomyocyte CL:0002131 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves ventricular cardiomyocyte, annotated with regular ventricular cardiac myocyte (CL:0002131). CL:0002131 is a cell type from the Cell Ontology.
Downstream
Cardiomyocyte Dystrophin-Glycoprotein Complex Disruption Loss of dystrophin removes the core structural component of the DGC at the cardiomyocyte sarcolemma.
Show evidence (3 references)
PMID:22455600 SUPPORT In Vitro
"In X-linked dilated cardiomyopathy due to dystrophin mutations which abolish the expression of the M isoform (5'-XLDC), the skeletal muscle is spared through the up-regulation of the Brain (B) isoform, a compensatory mechanism that does not appear to occur in the heart of affected individuals."
States the compensation-and-failure logic directly: skeletal muscle is rescued by the B isoform, the heart is not.
PMID:22455600 SUPPORT DIRECT In Vitro
"Unlike the M isoform, consistently detectable in all the heart regions, the B isoform was selectively expressed in atrial cardiomyocytes, but absent in ventricles and in conduction system structures."
The molecular-topography finding that grounds ventricular selectivity: no B isoform is available in the ventricle to replace the lost M isoform.
PMID:22455600 SUPPORT In Vitro
"The ventricular dilatation seen in 5'-XLDC patients appears to be functionally related to loss of the M isoform, the only isoform transcribed in human ventricles"
Ties the molecular finding to the clinical outcome (ventricular dilation) that the downstream chain models.
Cardiomyocyte Dystrophin-Glycoprotein Complex Disruption
Dystrophin is the central member of the dystrophin-glycoprotein complex (DGC) at the sarcolemma, linking the intracellular actin cytoskeleton through dystroglycan and sarcoglycan subcomplexes to the extracellular matrix. Without dystrophin the DGC cannot assemble, and the mechanical and signaling link across the ventricular cardiomyocyte membrane is lost.
dystrophin-glycoprotein complex at the sarcolemma GO:0016010 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves decreased dystrophin-glycoprotein complex at the sarcolemma, annotated with dystrophin-associated glycoprotein complex (GO:0016010). GO:0016010 is a cellular component from the Gene Ontology. cardiomyocyte sarcolemma GO:0042383 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves cardiomyocyte sarcolemma, annotated with sarcolemma (GO:0042383). GO:0042383 is a cellular component from the Gene Ontology.
Downstream
Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury A DGC-deficient sarcolemma cannot withstand the mechanical stress of contraction.
Show evidence (2 references)
PMID:36168044 SUPPORT Other
"Dystrophin connects the actin cytoskeleton to the extracellular matrix (ECM). Severing the link between the ECM and the intracellular cytoskeleton has a devastating impact on the homeostasis of skeletal muscle cells, leading to a range of muscular dystrophies. In addition, the loss of a..."
States both the DGC's structural role and that losing it causes progressive dilated cardiomyopathy - the claim this node makes.
PMID:26066469 SUPPORT Other
"Localized to the sarcolemma, dystrophin is a major component of the dystrophin glycoprotein complex (DGC) along with the dystroglycan, sarcoglycan, and syntrophin/dystrobrevin complexes that link the cytoskeletal protein actin to the basal lamina of muscle fibers"
Places dystrophin as the core DGC component at the sarcolemma, the structure this node loses.
Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury
With the DGC gone, dystrophin can no longer act as the molecular spring that protects the membrane during contraction, so each cardiac cycle inflicts microtears on the ventricular cardiomyocyte sarcolemma. This is the primary cardiomyocyte insult that the maladaptive-remodeling module models generically; here it is driven specifically by the ventricular dystrophin deficit and is aggravated by mechanical loading (the "use hypothesis").
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Animal models
Golden Retriever Muscular Dystrophy (GRMD) dog Dog partially recapitulates Reproduces the dystrophin-loss membrane-fragility-and-necrosis mechanism in a large-animal system with a human-like progressive course.
Downstream
Cardiomyocyte Calcium Overload Membrane microdamage admits pathological calcium influx into the cardiomyocyte.
Elevated Creatine Kinase Sarcolemmal microtears leak creatine kinase into the circulation, though variably in this cardiac-predominant phenotype.
Show evidence (2 references)
PMID:26066469 SUPPORT Other
"Dystrophin deficiency disrupts the DGC and causes the muscle membrane fragility and an increase in susceptibility to the mechanical stress, which leads to progressive muscle necrosis and degeneration in both skeletal and cardiac muscles"
The membrane-fragility-under-mechanical-stress mechanism, stated for cardiac as well as skeletal muscle.
PMID:36168044 SUPPORT Other
"Dystrophin functions as a molecular spring and the DGC plays a critical role in maintaining the integrity of the sarcolemma."
The molecular-spring/membrane-integrity function whose loss produces contraction-induced injury.
Cardiomyocyte Calcium Overload
Sarcolemmal microdamage and disrupted mechanosensitive channel regulation admit excess calcium into the ventricular cardiomyocyte, and intracellular calcium handling becomes overwhelmed. Calcium overload activates calcium-dependent proteases and injures mitochondria, driving the cell-death programme downstream.
intracellular calcium ion overload GO:0006874 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal intracellular calcium ion overload, annotated with intracellular calcium ion homeostasis (GO:0006874). GO:0006874 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Cardiomyocyte Necrosis and Replacement Fibrosis Sustained calcium overload triggers cardiomyocyte death and secondary fibrosis.
Show evidence (1 reference)
PMID:32075145 SUPPORT Other
"Sarcolemmal instability, leading to calcium mishandling and overload in the cardiac myocyte, is a key mechanistic contributor to muscle cell death, fibrosis, and diminished cardiac contractile function in DMD patients."
Places calcium overload as the link between sarcolemmal instability and the cell death, fibrosis and contractile failure of the downstream nodes.
Cardiomyocyte Necrosis and Replacement Fibrosis
Chronic calcium overload and membrane injury cause cardiomyocyte necrosis, with secondary replacement fibrosis and fatty infiltration that characteristically begin in the left ventricular posterobasal/inferolateral wall - the territory that lights up as late gadolinium enhancement on cardiac MRI across dystrophinopathy cardiomyopathy.
cardiac fibroblast CL:0002548 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac fibroblast, annotated with fibroblast of cardiac tissue (CL:0002548). CL:0002548 is a cell type from the Cell Ontology.
cardiomyocyte necrotic cell death GO:0008219 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cardiomyocyte necrotic cell death, annotated with cell death (GO:0008219). GO:0008219 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Left Ventricular Dilation and Systolic Heart Failure Cumulative myocyte loss and fibrotic replacement impair contraction and dilate the ventricle.
Show evidence (2 references)
PMID:26066469 SUPPORT Other
"Dystrophin deficiency disrupts the DGC and causes the muscle membrane fragility and an increase in susceptibility to the mechanical stress, which leads to progressive muscle necrosis and degeneration in both skeletal and cardiac muscles"
Names progressive necrosis and degeneration of cardiac muscle as the tissue-level consequence of the dystrophin deficit.
PMID:32075145 SUPPORT Other
"is a key mechanistic contributor to muscle cell death, fibrosis, and diminished cardiac contractile function in DMD patients."
Couples cell death with fibrosis and contractile decline, the transition this node makes to the heart-failure outcome.
Left Ventricular Dilation and Systolic Heart Failure
The clinical endpoint: progressive left ventricular dilation with systolic dysfunction, presenting as congestive heart failure. In classic XLDCM this is rapid and lethal in adolescent and young-adult males; in the exon 45-55 subtype it is more indolent and more responsive to standard heart-failure therapy. The failing, fibrotic ventricle also provides the substrate for ventricular arrhythmia and sudden cardiac death.
impaired cardiac muscle contraction GO:0060048 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased impaired cardiac muscle contraction, annotated with cardiac muscle contraction (GO:0060048). GO:0060048 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
mdx mouse Mouse partially recapitulates Reproduces dystrophin-deficient dilated cardiomyopathy but only mildly and late, under-representing the severity and tempo of the human ventricular failure.
Cmah-/-;mdx mouse Mouse recapitulates Displays earlier ventricular functional deterioration than standard mdx, better approximating the human cardiac course.
Downstream
Congestive Heart Failure
Dilated Cardiomyopathy
Reduced Left Ventricular Ejection Fraction
Dilated Cardiomyopathy in Heterozygous Female Carriers In heterozygous carrier females the same structural endpoint manifests later and more mildly, its expression governed by skewed X-inactivation.
Ventricular Arrhythmogenesis Myocyte loss and fibrosis create a re-entrant/ectopic arrhythmic substrate.
Show evidence (2 references)
PMID:26066469 SUPPORT Other
"XLDCM is caused by mutations of the Duchenne muscular dystrophy (DMD) gene and results in lethal heart failure in individuals between 10 and 20 years."
The heart-failure outcome and its characteristic age window in males.
PMID:8504498 SUPPORT Human Clinical
"X-linked cardiomyopathy (XLCM) is a rapidly progressive primary myocardial disorder presenting in teenage males as congestive heart failure."
The clinical presentation this node describes, from the original linkage cohort.
Ventricular Arrhythmogenesis
A fibrotic, dilated ventricle is electrically unstable: replacement fibrosis and myocyte loss create a re-entrant/ectopic substrate that generates ventricular arrhythmia, a major contributor to mortality in XLDCM.
Downstream
Ventricular Arrhythmia
Arrhythmic Sudden Cardiac Death A sustained malignant ventricular arrhythmia can precipitate fatal circulatory arrest.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"showed rapidly progressive heart failure and ventricular arrhythmias between 10 and 20 years old."
Ventricular arrhythmia arising in the failing dystrophin-deficient ventricle of the founding XLDCM kindred.
Arrhythmic Sudden Cardiac Death
Sudden cardiac death can be the presenting event, occurring without preceding overt heart failure - documented at autopsy by elevated pericardial-fluid NT-proBNP marking undiagnosed left ventricular dysfunction.
Downstream
Sudden Cardiac Death
Show evidence (1 reference)
PMID:32939432 SUPPORT Human Clinical
"The cause of death was certified as an early dilated cardiomyopathy (DCM)/dysfunction of the left ventricle secondary to DMD"
A documented case of sudden death from dystrophin-deficient dilated cardiomyopathy, the terminal event this node models.
✶

Histopathology

2
Absent/Reduced Myocardial Dystrophin on Immunostaining
Immunohistochemical staining of cardiac (or skeletal) muscle shows absence or reduction of dystrophin, confirming the molecular diagnosis even when skeletal strength is normal.
Show evidence (1 reference)
PMID:32939432 SUPPORT Human Clinical
"Total absence of dystrophin was detected by immunohistochemical staining, which confirmed DMD."
Absence of dystrophin on immunostaining is the confirmatory histopathologic finding.
Cardiomyocyte Degeneration with Enlarged Heart
The heart is enlarged (dilated) with disarray and degeneration of cardiomyocytes, the tissue correlate of the replacement fibrosis and myocyte loss modeled in the pathograph.
Show evidence (1 reference)
PMID:32939432 SUPPORT Human Clinical
"The heart was enlarged with disarray and degeneration of cardiomyocytes in cardiac muscle."
Autopsy histology of the dilated, degenerating dystrophin-deficient myocardium.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for X-linked Dilated Cardiomyopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Cardiovascular 6
Dilated Cardiomyopathy VERY_FREQUENT HP:0001644 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dilated cardiomyopathy (HP:0001644), qualified as course progressive. HP:0001644 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"X-linked dilated cardiomyopathy (XLDCM) is a distinct phenotype of dystrophinopathy characterized by preferential cardiac involvement without any overt skeletal myopathy."
States both the defining cardiac phenotype and its isolation from skeletal disease.
Congestive Heart Failure VERY_FREQUENT HP:0001635 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congestive heart failure (HP:0001635). HP:0001635 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:8504498 SUPPORT Human Clinical
"X-linked cardiomyopathy (XLCM) is a rapidly progressive primary myocardial disorder presenting in teenage males as congestive heart failure."
Congestive heart failure as the presenting manifestation in teenage males.
Reduced Left Ventricular Ejection Fraction HP:0012664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced left ventricular ejection fraction (HP:0012664). HP:0012664 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40130400 SUPPORT INDIRECT Human Clinical
"Absolute LVEF% values reduced in both groups ('active': 62.5% ± 5.6% to 53.8% ± 4.0%; 'placebo': 60.6% ± 4.9% to 50.4% ± 8.5%)."
Documents the progressive fall in left ventricular ejection fraction over follow-up in dystrophin-deficient cardiomyopathy; measured in a DMD cohort and applied to XLDCM as the same dystrophin-deficient cardiomyopathy, hence INDIRECT.
Ventricular Arrhythmia FREQUENT HP:0004308 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ventricular arrhythmia (HP:0004308). HP:0004308 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"showed rapidly progressive heart failure and ventricular arrhythmias between 10 and 20 years old."
Ventricular arrhythmia alongside heart failure in the affected males of the founding XLDCM kindred.
Sudden Cardiac Death HP:0001645 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sudden cardiac death (HP:0001645). HP:0001645 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32939432 SUPPORT Human Clinical
"Here, we reported a case of 29-year-old man who died suddenly."
A documented sudden death from previously undiagnosed dystrophin-deficient cardiomyopathy.
Dilated Cardiomyopathy in Heterozygous Female Carriers HP:0001644 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dilated cardiomyopathy (HP:0001644), qualified as adult onset. HP:0001644 is a phenotype from the Human Phenotype Ontology.
Onset: ADULT
Show evidence (1 reference)
PMID:32650403 SUPPORT Other
"It is known that about 8% of carriers present with dilated cardiomyopathy, though it may vary from 0% to 16.7%, depending on if the carrier is classified as having DMD or BMD."
Quantifies the carrier-female cardiomyopathy risk and its range across DMD/BMD carrier classes.
Metabolism 1
Elevated Creatine Kinase OCCASIONAL Elevated circulating creatine kinase concentration HP:0003236 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating creatine kinase concentration (HP:0003236). HP:0003236 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10841222 SUPPORT Human Clinical
"Serum CPK levels were increased in 11 of 13 patients."
Creatine phosphokinase was elevated in most, but not all, dystrophin-defect DCM patients, consistent with a variable, non-discriminating CK.
🧬

Genetic Associations

1
DMD
Gene: DMD hgnc:2928 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is DMD (hgnc:2928). hgnc:2928 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
X-linked recessive
Show evidence (2 references)
PMID:8504498 SUPPORT Human Clinical
"XLCM is due to an abnormality within the centromeric half of the dystrophin genomic region in heart."
Localizes the causal lesion to the dystrophin (DMD) gene, establishing XLDCM as a dystrophinopathy.
PMID:18261911 SUPPORT Human Clinical
"Two younger patients diagnosed as having X-linked dilated cardiomyopathy (XLDCM) developed congestive heart failure without overt skeletal myopathy."
Documents the exon 45-55 in-frame deletion class producing cardiac-predominant XLDCM without skeletal myopathy.
💊

Medical Actions

5
Heart Failure Pharmacotherapy (ACE Inhibitor and Beta-Blocker)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ACE inhibitor NCIT:C247 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses ACE inhibitor (NCIT:C247). NCIT:C247 is a therapeutic agent from the NCI Thesaurus. beta-adrenergic antagonist NCIT:C29576 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses beta-adrenergic antagonist (NCIT:C29576). NCIT:C29576 is a therapeutic agent from the NCI Thesaurus.
Platform: Small molecule
Standard heart-failure guideline-directed medical therapy is the mainstay for the dilated cardiomyopathy: an ACE inhibitor, usually combined with a beta-blocker. Combination therapy improved left ventricular function relative to ACE-inhibitor monotherapy in the dystrophinopathy-cardiomyopathy literature. An important recent caveat from the DMD Heart Protection Study long-term follow-up is that starting therapy prophylactically (before detectable dysfunction) did not produce a group-mean ejection-fraction advantage over starting at first detected dysfunction, though the trial notes small numbers and echo insensitivity - so early detection and prompt treatment at first dysfunction is the defensible strategy rather than universal prophylaxis.
Mechanism Target:
INHIBITS Left Ventricular Dilation and Systolic Heart Failure — Standard neurohormonal-blockade heart-failure therapy acting on the ventricular remodeling and failure endpoint rather than on the dystrophin deficit.
Show evidence (1 reference)
PMID:40130400 SUPPORT INDIRECT Human Clinical
"DMD Care Standards recommend starting angiotensin‐converting enzyme inhibitor (ACEi) medication empirically no later than the age of 10 years"
The standard-of-care recommendation to treat dystrophin-deficient cardiomyopathy with an ACE inhibitor.
Show evidence (1 reference)
PMID:40130400 SUPPORT INDIRECT Human Clinical
"While some patients may have benefited from 'early' (active) as opposed to 'delayed' (placebo) initiation of perindopril and bisoprolol, group-mean ventricular function did not differ between study arms after 60 months."
The prophylaxis-versus-treat-at-detection nuance that qualifies how this therapy is timed.
Angiotensin Receptor Blocker (Losartan) as ACE-Inhibitor Alternative
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: angiotensin II receptor antagonist NCIT:C66930 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses angiotensin II receptor antagonist (NCIT:C66930). NCIT:C66930 is a therapeutic agent from the NCI Thesaurus. losartan CHEBI:6541 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses losartan (CHEBI:6541). CHEBI:6541 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
An angiotensin receptor blocker such as losartan is an accepted alternative to an ACE inhibitor; a randomized double-blind trial of lisinopril versus losartan in dystrophin-deficient cardiomyopathy found both effective without establishing superiority of either.
Mechanism Target:
INHIBITS Left Ventricular Dilation and Systolic Heart Failure — Renin-angiotensin blockade as an alternative to ACE inhibition for the failing ventricle.
Show evidence (1 reference)
PMID:24459612 SUPPORT INDIRECT Human Clinical
"There is no therapeutic difference in EF improvement between lisinopril and losartan over the one-year duration for treatment of boys with DMD-related CM."
The randomized trial establishing losartan (ARB) as equivalent to lisinopril (ACE inhibitor) for dystrophin-deficient cardiomyopathy, supporting the ARB as an alternative.
Heart Transplantation
Action: cardiac transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cardiac transplantation, annotated with Organ Transplantation (NCIT:C15289). NCIT:C15289 is a clinical intervention from the NCI Thesaurus. Ontology label: Organ Transplantation NCIT:C15289
Platform: Surgery
The only curative option for end-stage dystrophin-deficient heart failure refractory to medical therapy. XLDCM is a favorable transplant setting precisely because skeletal and respiratory function is typically preserved - the comorbidity that complicates transplant candidacy in classic Duchenne is largely absent here - and post-transplant outcomes are comparable to non-dystrophinopathy recipients.
Mechanism Target:
BYPASSES Left Ventricular Dilation and Systolic Heart Failure — Replaces the failing organ rather than acting on the dystrophin deficit, which persists in the remaining tissues.
Show evidence (1 reference)
PMID:28580208 SUPPORT Other
"Heart transplantation (HT) is the only curative therapy for patients with dystrophinopathic end-stage heart failure who remain symptomatic despite an optimal medical therapy."
States transplantation as the only curative option for end-stage dystrophinopathic cardiomyopathy.
Show evidence (2 references)
PMID:28580208 SUPPORT Other
"heart transplantation is a safe and effective treatment for selected patients with end-stage DCM."
The authors' conclusion supporting transplantation in selected dystrophinopathic DCM patients.
PMID:20301298 SUPPORT Other
"cardiac transplantation is offered to persons with severe dilated cardiomyopathy and BMD with limited or no clinical evidence of skeletal muscle disease"
GeneReviews states that transplantation is offered when skeletal muscle disease is limited or absent - precisely the XLDCM situation that makes it a favorable candidate.
Cardiac Surveillance (Including Carrier Females)
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Other
Because subclinical cardiac dysfunction precedes symptoms and skeletal severity does not predict cardiac involvement, baseline and serial cardiac evaluation (ECG, echocardiography, and cardiac MRI for late gadolinium enhancement) is standard from diagnosis in affected individuals. Heterozygous carrier females need surveillance too, given their real, X-inactivation-dependent cardiomyopathy risk.
Show evidence (2 references)
PMID:32650403 SUPPORT Other
"Cardiac symptoms are particularly prevalent in female dystrophin mutation carriers, affecting about 8% of this population with dilated cardiomyopathy (DCM) as a common presentation"
The carrier cardiac risk that justifies extending surveillance to heterozygous females.
PMID:20301298 SUPPORT Other
"For heterozygous females: cardiac evaluation at least once after the teenage years"
GeneReviews' explicit surveillance recommendation for heterozygous carrier females.
Device Therapy (ICD and Cardiac Resynchronization Therapy)
Action: cardiac resynchronization therapy device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cardiac resynchronization therapy device implantation, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Device
For advanced disease, an implantable cardioverter-defibrillator addresses the ventricular arrhythmia / sudden-death risk, and cardiac resynchronization therapy (biventricular pacing) is used when heart failure is complicated by ventricular dyssynchrony.
Mechanism Target:
INHIBITS Ventricular Arrhythmogenesis — Device therapy targets the arrhythmic substrate and dyssynchronous failure rather than the dystrophin deficit.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"cardiac resynchronization therapy (biventricular pacing), is appropriate for cases of heart failure with associated ventricular dyssynchrony"
The review's statement of CRT indication in dystrophinopathy cardiomyopathy with ventricular dyssynchrony.
🔬

Biochemical Markers

1
NT-proBNP (INCREASED)
Context: N-terminal pro-B-type natriuretic peptide is the best-validated serum biomarker for detecting and tracking systolic dysfunction in dystrophin-deficient cardiomyopathy and is the practical analyte for longitudinal follow-up. Elevated pericardial-fluid NT-proBNP has also marked previously undiagnosed left ventricular dysfunction at autopsy in sudden death.
Show evidence (2 references)
PMID:32939432 SUPPORT Human Clinical
"N-terminal-proBNP (NT-proBNP) was a robust laboratory biomarker to diagnose and monitor cardiac failure in clinical situations"
Establishes NT-proBNP as a validated biomarker for cardiac failure, here applied to dystrophin-deficient left ventricular dysfunction.
PMID:34429516 SUPPORT INDIRECT Human Clinical
"NT-proBNP correlated with indexed left ventricular end diastolic and maximum left atrial volumes."
NT-proBNP tracked left ventricular and atrial volumes in a DMD cohort; applied to XLDCM as the same dystrophin-deficient cardiomyopathy, hence INDIRECT.
🔬

Diagnosis

5
DMD Molecular Genetic Testing (Deletion/Duplication Analysis then Sequencing)
XLDCM is confirmed by identifying a pathogenic DMD variant. Multiplex ligation-dependent probe amplification (MLPA) or targeted deletion/duplication analysis is the first-tier test because most dystrophinopathy lesions are deletions/duplications; full-gene sequencing follows to detect the point mutations, small indels, and splice/deep-intronic variants that MLPA cannot see.
Show evidence (2 references)
PMID:20301298 SUPPORT Other
"identification of a hemizygous pathogenic variant in DMD on molecular genetic testing in a male and of a heterozygous pathogenic variant in DMD on molecular genetic testing in a female"
GeneReviews states how a dystrophinopathy diagnosis is molecularly established in males and in carrier females.
PMID:26066469 SUPPORT Other
"The definitive diagnosis is defined by the identification of the DMD gene mutations by gene analysis such as multiplex-PCR or multiplex ligation dependent probe amplification (MLPA)."
Names MLPA as the definitive molecular diagnostic method for XLDCM.
Muscle-Promoter / Exon-1-Specific Analysis
Because the paradigmatic 5' XLDCM lesion is a deletion of the muscle promoter and first muscle exon, testing that specifically covers the 5' promoter/exon-1 region is important when a cardiac-predominant phenotype with normal or near-normal strength is seen - standard multi-exon deletion panels can under-detect an isolated promoter-region lesion.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"the causative mutation would include a deletion in the region and in exon 1"
Documents the muscle-promoter/exon-1 location of the causative lesion that motivates 5'-specific testing.
Electrocardiography (Characteristic Dystrophinopathy Pattern)
A characteristic (though not pathognomonic) ECG pattern - tall R waves with high R/S ratio in the right precordial leads and deep lateral/inferior Q waves - is often present, sometimes before symptomatic heart failure, and is part of baseline and surveillance evaluation.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"The electrocardiogram (ECG) in dystrophinopathy shows high R waves (R/S > 1) in the right precordial leads (V1-2), deep Q waves in leads I, aVL, and V5-6 or in leads II, III, and aVF"
The characteristic dystrophinopathy ECG signature used in XLDCM evaluation.
Cardiac Imaging (Echocardiography and Cardiac MRI)
Echocardiography is the first-line serial modality for left ventricular size and function. Cardiac MRI adds late gadolinium enhancement (LGE), the imaging correlate of the posterobasal/inferolateral fibrofatty replacement, which can precede overt systolic dysfunction on echo.
Show evidence (2 references)
PMID:26066469 SUPPORT Other
"Echocardiography results include myocardial thickening, wall motion abnormalities, enlargement of the left ventricle, and left ventricular systolic or diastolic dysfunction"
The echocardiographic findings tracked in XLDCM cardiac surveillance.
PMID:34429516 SUPPORT INDIRECT Human Clinical
"Those with elevated cTnI were more likely to have late gadolinium enhancement on baseline CMR."
Documents CMR late gadolinium enhancement in a DMD cohort; applied to XLDCM as the same dystrophin-deficient cardiomyopathy, hence INDIRECT.
Agents / Circumstances to Avoid (Anesthesia)
Dystrophinopathy patients are susceptible to malignant-hyperthermia-like reactions; succinylcholine and inhalational (volatile) anesthetics should be avoided. This is clinically important in XLDCM given that these patients may undergo cardiac surgery or heart transplantation.
Show evidence (1 reference)
PMID:20301298 SUPPORT Other
"succinylcholine and inhalational anesthetics because of susceptibility to malignant hyperthermia or malignant hyperthermia-like reactions"
GeneReviews lists succinylcholine and inhalational anesthetics among the agents/circumstances to avoid in dystrophinopathy.
📈

Progression

2
Classic 5' XLDCM (rapid)
5-prime XLDCM Age: 10-20 years (males)
Rapidly progressive; in the original kindred affected males died within 5 to 12 months of symptom onset.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"die of heart failure between 10 and 20 years old"
The rapid, lethal course of classic XLDCM in males.
Exon 45-55 deletion (indolent)
Exon 45-55
Milder, treatment-responsive course with relatively good life expectancy.
Show evidence (1 reference)
PMID:26066469 SUPPORT Other
"they usually have a good life expectancy"
The more indolent prognosis of the exon 45-55 hotspot subtype.
📊

Prevalence

1
Isolated cardiac (skeletal-sparing) XLDCM
Unknown Not yet documented
No population-based prevalence estimate exists for the isolated cardiac XLDCM phenotype, which is historically defined by individual pedigrees rather than registries. The available numbers are diagnostic yields, not population rates: DMD defects were found in 6.5% (13/201) of consecutive adult male DCM patients screened by Arbustini et al., and 3% of a Japanese adult DCM cohort. These are the fraction of "idiopathic" male DCM attributable to dystrophin, not the occurrence of XLDCM in the general population, and must not be compared with a whole-population prevalence.
Show evidence (1 reference)
PMID:10841222 SUPPORT Human Clinical
"Dystrophin defects were identified in 13 of the 201 patients (6.5%, age 16-50)."
The diagnostic yield of dystrophin defects among consecutive male DCM patients, quoted as a yield and not a population prevalence.
🐁

Animal Models

3
mdx mouse
The standard, most widely used DMD mouse model. It develops a dilated cardiomyopathy with decreased fractional shortening, but the cardiac phenotype is mild and late-onset relative to human disease - a recognized model limitation.
Species
Mouse
Genotype
Dmd (mdx) dystrophin-null point mutation
Publication
PMID:30281092
Pathograph links
Left Ventricular Dilation and Systolic Heart Failure partially recapitulates fidelity: low Reproduces dystrophin-deficient dilated cardiomyopathy but only mildly and late, under-representing the severity and tempo of the human ventricular failure.
Limitations: Standard mouse models do not recapitulate all aspects of human disease pathology and exhibit only a mild cardiac phenotype; they also carry combined skeletal-plus-cardiac dystrophin loss rather than the cardiac-selective XLDCM lesion.
Show evidence (1 reference)
PMID:30281092 SUPPORT Model Organism
"Several mouse models have been developed to study molecular and pathological consequences of dystrophin deficiency, but do not recapitulate all aspects of human disease pathology and exhibit a mild cardiac phenotype."
States the mdx/mouse cardiac-phenotype limitation directly.
Cmah-/-;mdx mouse
An enhanced double-knockout model in which loss of CMP-sialic acid hydroxylase on the mdx background accelerates the cardiac phenotype toward the human course, used to evaluate cardiac-directed DMD therapeutics.
Species
Mouse
Genotype
Cmah-null on mdx dystrophin-null background (Cmah-/-;mdx)
Publication
PMID:30281092
Pathograph links
Left Ventricular Dilation and Systolic Heart Failure recapitulates fidelity: moderate Displays earlier ventricular functional deterioration than standard mdx, better approximating the human cardiac course.
Limitations: The acceleration is engineered through a Cmah-null background rather than the human isoform-topography mechanism, and the model is not skeletal-sparing, so it does not reproduce the cardiac-selective XLDCM phenotype.
Readouts
Right ventricular ejection fraction and stroke volume
Direction: DECREASED
Interpretation: Earlier decline in ventricular function than in standard mdx, the functional correlate of the accelerated cardiomyopathy.
Show evidence (1 reference)
PMID:30281092 SUPPORT Model Organism
"reduction in right ventricle (RV) ejection fraction and stroke volume (SV) at 12 weeks of age"
The measured ventricular-function deficit in this model.
Show evidence (1 reference)
PMID:30281092 SUPPORT Model Organism
"have an accelerated cardiac phenotype compared to the established mdx model"
Establishes the accelerated cardiac phenotype that makes this an informative cardiac model.
Golden Retriever Muscular Dystrophy (GRMD) dog
A naturally occurring, genetically homologous canine dystrophinopathy whose more severe, progressive clinical course aligns better with human DMD than rodent models do, used as a translational large-animal model including for cardiac studies.
Species
Dog
Genotype
DMD splice-site mutation causing exon skipping and an out-of-frame transcript
Publication
PMID:28526070
Pathograph links
Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury partially recapitulates fidelity: moderate Reproduces the dystrophin-loss membrane-fragility-and-necrosis mechanism in a large-animal system with a human-like progressive course.
Limitations: GRMD models the combined skeletal-plus-cardiac dystrophinopathy rather than an isolated cardiac-selective analog of XLDCM, and cost/availability limit its use.
Show evidence (1 reference)
PMID:28526070 SUPPORT Model Organism
"The absence of dystrophin leads to myofiber membrane fragility and necrosis, with eventual muscle atrophy and contractures."
States the membrane-fragility-and-necrosis mechanism this model recapitulates.
Show evidence (1 reference)
PMID:28526070 SUPPORT Model Organism
"Because the GRMD clinical syndrome is more severe than in mice, better aligning with the progressive course of DMD, canine studies may translate better to humans."
The translational rationale for using GRMD as a large-animal dystrophinopathy model.
{ }

Source YAML

click to show 
name: X-linked Dilated Cardiomyopathy
creation_date: "2026-09-03T00:00:00Z"
category: Mendelian
synonyms:
- XLDCM
- XLCM
- dilated cardiomyopathy 3B
- CMD3B
- cardiomyopathy, dilated, X-linked
- DMD-associated dilated cardiomyopathy
- cardiac-specific dystrophinopathy
- 5' X-linked dilated cardiomyopathy
disease_term:
  preferred_term: X-linked dilated cardiomyopathy
  term:
    id: MONDO:0010542
    label: dilated cardiomyopathy 3B
description: >-
  The cardiac-selective dystrophinopathy. XLDCM is caused by mutations in DMD -
  the same gene as Duchenne and Becker muscular dystrophy - but expressed almost
  exclusively as dilated cardiomyopathy, with minimal or absent skeletal
  myopathy. What makes it a distinct entry rather than "the heart part of
  Duchenne" is where in the gene the lesion falls and how tissue-specific
  dystrophin promoters respond to it.

  The paradigmatic lesion is a deletion of the muscle (M) promoter and first
  muscle exon at the 5' end of DMD. This abolishes the muscle dystrophin isoform
  (Dp427m) everywhere it is normally made, but skeletal muscle rescues itself by
  up-regulating the brain (B) and Purkinje (P) isoforms from intact downstream
  promoters. The ventricular myocardium cannot: the B isoform is expressed in
  human heart only in the atria and conduction tissue, not in the ventricles, so
  there is no compensatory transcript available where it matters. The result is a
  loss of dystrophin that is functionally confined to the ventricle - the direct
  molecular explanation for a dystrophinopathy that devastates the heart while
  sparing the limbs.

  The clinical shape follows the molecular one and is starkly sex-dependent.
  Hemizygous males present in adolescence or the early twenties with rapidly
  progressive heart failure and ventricular arrhythmia; in the original kindred,
  affected males died within 5 to 12 months of symptom onset. Heterozygous
  carrier females are not unaffected - they develop a milder, later-onset dilated
  cardiomyopathy in the fourth to fifth decade, its severity tracking skewed
  X-inactivation. Because there is little or no skeletal weakness to raise
  suspicion, XLDCM is readily mistaken for idiopathic dilated cardiomyopathy, and
  DMD defects account for a small but real fraction of young-adult male DCM.
parents:
- Dilated Cardiomyopathy
- Dystrophinopathy
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: GENETICS_ENVIRONMENT_DISEASE

pathophysiology:
- name: 5' DMD Muscle-Promoter/Isoform-Disrupting Lesion
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion. The paradigmatic XLDCM mutation deletes the muscle (M)
    promoter and first muscle exon at the 5' end of DMD, abolishing transcription
    of the muscle dystrophin isoform (Dp427m); other XLDCM lesions include
    in-frame exon 45-55 deletions and destabilizing missense variants. Towbin's
    linkage study localized the disorder to the centromeric half of the dystrophin
    locus at Xp21 and showed that cardiac dystrophin was abnormal on Western blot
    while skeletal-muscle dystrophin was normal - the biochemical signature of a
    heart-preferential dystrophin defect.
  molecular_functions:
  - preferred_term: dystrophin actin filament binding
    term:
      id: GO:0051015
      label: actin filament binding
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:8504498
    reference_title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Linkage of XLCM to the centromeric portion of the dystrophin or Duchenne
      muscular dystrophy (DMD) locus at Xp21 was demonstrated with combined maximum
      logarithm of the scores of +4.33
    explanation: >-
      Establishes DMD at Xp21 as the disease locus, the founding molecular evidence
      that XLDCM is a dystrophinopathy.
  - reference: PMID:8504498
    reference_title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormalities of cardiac dystrophin were shown by Western blotting with
      N-terminal dystrophin antibody, whereas skeletal muscle dystrophin was normal,
      suggesting primary involvement of the DMD gene with preferential involvement of
      cardiac muscle.
    explanation: >-
      The heart-selective biochemical defect that defines the entity: abnormal cardiac
      dystrophin against normal skeletal-muscle dystrophin.
  downstream:
  - target: Ventricle-Selective Loss of Dystrophin
    causal_link_type: DIRECT
    description: >-
      Abolishing the muscle isoform sets up a tissue-specific failure of compensation
      that is resolved at the next node.

- name: Ventricle-Selective Loss of Dystrophin
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    The node on which the whole entry turns, and the reason XLDCM is cardiac-selective
    rather than a systemic dystrophinopathy. When the 5' mutation abolishes the muscle
    (M) dystrophin isoform, skeletal muscle compensates by up-regulating the brain (B)
    isoform from an intact downstream promoter. The ventricular myocardium cannot: in
    the healthy human heart the B isoform is expressed only in atrial cardiomyocytes and
    conduction tissue, and is absent from the ventricles, which transcribe the M isoform
    alone. With no compensatory transcript available, the ventricle is left
    dystrophin-deficient while the limbs are rescued.
  cell_types:
  - preferred_term: ventricular cardiomyocyte
    term:
      id: CL:0002131
      label: regular ventricular cardiac myocyte
  evidence:
  - reference: PMID:22455600
    reference_title: "The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In X-linked dilated cardiomyopathy due to dystrophin mutations which abolish the
      expression of the M isoform (5'-XLDC), the skeletal muscle is spared through the
      up-regulation of the Brain (B) isoform, a compensatory mechanism that does not
      appear to occur in the heart of affected individuals.
    explanation: >-
      States the compensation-and-failure logic directly: skeletal muscle is rescued by
      the B isoform, the heart is not.
  - reference: PMID:22455600
    reference_title: "The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    snippet: >-
      Unlike the M isoform, consistently detectable in all the heart regions, the B
      isoform was selectively expressed in atrial cardiomyocytes, but absent in
      ventricles and in conduction system structures.
    explanation: >-
      The molecular-topography finding that grounds ventricular selectivity: no B isoform
      is available in the ventricle to replace the lost M isoform.
  - reference: PMID:22455600
    reference_title: "The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The ventricular dilatation seen in 5'-XLDC patients appears to be functionally
      related to loss of the M isoform, the only isoform transcribed in human ventricles
    explanation: >-
      Ties the molecular finding to the clinical outcome (ventricular dilation) that the
      downstream chain models.
  downstream:
  - target: Cardiomyocyte Dystrophin-Glycoprotein Complex Disruption
    causal_link_type: DIRECT
    description: >-
      Loss of dystrophin removes the core structural component of the DGC at the
      cardiomyocyte sarcolemma.

- name: Cardiomyocyte Dystrophin-Glycoprotein Complex Disruption
  role: effector
  biological_scale: MOLECULAR
  description: >-
    Dystrophin is the central member of the dystrophin-glycoprotein complex (DGC) at the
    sarcolemma, linking the intracellular actin cytoskeleton through dystroglycan and
    sarcoglycan subcomplexes to the extracellular matrix. Without dystrophin the DGC
    cannot assemble, and the mechanical and signaling link across the ventricular
    cardiomyocyte membrane is lost.
  cellular_components:
  - preferred_term: dystrophin-glycoprotein complex at the sarcolemma
    term:
      id: GO:0016010
      label: dystrophin-associated glycoprotein complex
    modifier: DECREASED
  - preferred_term: cardiomyocyte sarcolemma
    term:
      id: GO:0042383
      label: sarcolemma
  evidence:
  - reference: PMID:36168044
    reference_title: "The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dystrophin connects the actin cytoskeleton to the extracellular matrix (ECM).
      Severing the link between the ECM and the intracellular cytoskeleton has a
      devastating impact on the homeostasis of skeletal muscle cells, leading to a range
      of muscular dystrophies. In addition, the loss of a functional DGC leads to
      progressive dilated cardiomyopathy and premature death.
    explanation: >-
      States both the DGC's structural role and that losing it causes progressive dilated
      cardiomyopathy - the claim this node makes.
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Localized to the sarcolemma, dystrophin is a major component of the dystrophin
      glycoprotein complex (DGC) along with the dystroglycan, sarcoglycan, and
      syntrophin/dystrobrevin complexes that link the cytoskeletal protein actin to the
      basal lamina of muscle fibers
    explanation: >-
      Places dystrophin as the core DGC component at the sarcolemma, the structure this
      node loses.
  downstream:
  - target: Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury
    causal_link_type: DIRECT
    description: >-
      A DGC-deficient sarcolemma cannot withstand the mechanical stress of contraction.

- name: Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury
  role: effector
  biological_scale: CELLULAR
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Primary Cardiomyocyte Insult"
  description: >-
    With the DGC gone, dystrophin can no longer act as the molecular spring that
    protects the membrane during contraction, so each cardiac cycle inflicts microtears
    on the ventricular cardiomyocyte sarcolemma. This is the primary cardiomyocyte
    insult that the maladaptive-remodeling module models generically; here it is driven
    specifically by the ventricular dystrophin deficit and is aggravated by mechanical
    loading (the "use hypothesis").
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dystrophin deficiency disrupts the DGC and causes the muscle membrane fragility and
      an increase in susceptibility to the mechanical stress, which leads to progressive
      muscle necrosis and degeneration in both skeletal and cardiac muscles
    explanation: >-
      The membrane-fragility-under-mechanical-stress mechanism, stated for cardiac as well
      as skeletal muscle.
  - reference: PMID:36168044
    reference_title: "The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dystrophin functions as a molecular spring and the DGC plays a critical role in
      maintaining the integrity of the sarcolemma.
    explanation: >-
      The molecular-spring/membrane-integrity function whose loss produces
      contraction-induced injury.
  downstream:
  - target: Cardiomyocyte Calcium Overload
    causal_link_type: DIRECT
    description: >-
      Membrane microdamage admits pathological calcium influx into the cardiomyocyte.
  - target: Elevated Creatine Kinase
    causal_link_type: DIRECT
    description: >-
      Sarcolemmal microtears leak creatine kinase into the circulation, though variably
      in this cardiac-predominant phenotype.

- name: Cardiomyocyte Calcium Overload
  role: effector
  biological_scale: CELLULAR
  description: >-
    Sarcolemmal microdamage and disrupted mechanosensitive channel regulation admit
    excess calcium into the ventricular cardiomyocyte, and intracellular calcium handling
    becomes overwhelmed. Calcium overload activates calcium-dependent proteases and
    injures mitochondria, driving the cell-death programme downstream.
  biological_processes:
  - preferred_term: intracellular calcium ion overload
    term:
      id: GO:0006874
      label: intracellular calcium ion homeostasis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32075145
    reference_title: "Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Sarcolemmal instability, leading to calcium mishandling and overload in the cardiac
      myocyte, is a key mechanistic contributor to muscle cell death, fibrosis, and
      diminished cardiac contractile function in DMD patients.
    explanation: >-
      Places calcium overload as the link between sarcolemmal instability and the cell
      death, fibrosis and contractile failure of the downstream nodes.
  downstream:
  - target: Cardiomyocyte Necrosis and Replacement Fibrosis
    causal_link_type: DIRECT
    description: >-
      Sustained calcium overload triggers cardiomyocyte death and secondary fibrosis.

- name: Cardiomyocyte Necrosis and Replacement Fibrosis
  role: effector
  biological_scale: TISSUE
  description: >-
    Chronic calcium overload and membrane injury cause cardiomyocyte necrosis, with
    secondary replacement fibrosis and fatty infiltration that characteristically begin
    in the left ventricular posterobasal/inferolateral wall - the territory that lights
    up as late gadolinium enhancement on cardiac MRI across dystrophinopathy
    cardiomyopathy.
  cell_types:
  - preferred_term: cardiac fibroblast
    term:
      id: CL:0002548
      label: fibroblast of cardiac tissue
  biological_processes:
  - preferred_term: cardiomyocyte necrotic cell death
    term:
      id: GO:0008219
      label: cell death
    modifier: INCREASED
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dystrophin deficiency disrupts the DGC and causes the muscle membrane fragility and
      an increase in susceptibility to the mechanical stress, which leads to progressive
      muscle necrosis and degeneration in both skeletal and cardiac muscles
    explanation: >-
      Names progressive necrosis and degeneration of cardiac muscle as the tissue-level
      consequence of the dystrophin deficit.
  - reference: PMID:32075145
    reference_title: "Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      is a key mechanistic contributor to muscle cell death, fibrosis, and diminished
      cardiac contractile function in DMD patients.
    explanation: >-
      Couples cell death with fibrosis and contractile decline, the transition this node
      makes to the heart-failure outcome.
  downstream:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    causal_link_type: DIRECT
    description: >-
      Cumulative myocyte loss and fibrotic replacement impair contraction and dilate the
      ventricle.

- name: Left Ventricular Dilation and Systolic Heart Failure
  role: outcome
  biological_scale: ORGANISM
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Structural Cardiac Impairment and Heart Failure"
  description: >-
    The clinical endpoint: progressive left ventricular dilation with systolic
    dysfunction, presenting as congestive heart failure. In classic XLDCM this is rapid
    and lethal in adolescent and young-adult males; in the exon 45-55 subtype it is more
    indolent and more responsive to standard heart-failure therapy. The failing,
    fibrotic ventricle also provides the substrate for ventricular arrhythmia and sudden
    cardiac death.
  biological_processes:
  - preferred_term: impaired cardiac muscle contraction
    term:
      id: GO:0060048
      label: cardiac muscle contraction
    modifier: DECREASED
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      XLDCM is caused by mutations of the Duchenne muscular dystrophy (DMD) gene and
      results in lethal heart failure in individuals between 10 and 20 years.
    explanation: >-
      The heart-failure outcome and its characteristic age window in males.
  - reference: PMID:8504498
    reference_title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      X-linked cardiomyopathy (XLCM) is a rapidly progressive primary myocardial disorder
      presenting in teenage males as congestive heart failure.
    explanation: >-
      The clinical presentation this node describes, from the original linkage cohort.
  downstream:
  - target: Congestive Heart Failure
    causal_link_type: DIRECT
  - target: Dilated Cardiomyopathy
    causal_link_type: DIRECT
  - target: Reduced Left Ventricular Ejection Fraction
    causal_link_type: DIRECT
  - target: Dilated Cardiomyopathy in Heterozygous Female Carriers
    causal_link_type: DIRECT
    description: >-
      In heterozygous carrier females the same structural endpoint manifests later and
      more mildly, its expression governed by skewed X-inactivation.
  - target: Ventricular Arrhythmogenesis
    causal_link_type: DIRECT
    description: >-
      Myocyte loss and fibrosis create a re-entrant/ectopic arrhythmic substrate.

- name: Ventricular Arrhythmogenesis
  role: effector
  biological_scale: ORGANISM
  description: >-
    A fibrotic, dilated ventricle is electrically unstable: replacement fibrosis and
    myocyte loss create a re-entrant/ectopic substrate that generates ventricular
    arrhythmia, a major contributor to mortality in XLDCM.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      showed rapidly progressive heart failure and ventricular arrhythmias between 10 and
      20 years old.
    explanation: >-
      Ventricular arrhythmia arising in the failing dystrophin-deficient ventricle of the
      founding XLDCM kindred.
  downstream:
  - target: Ventricular Arrhythmia
    causal_link_type: DIRECT
  - target: Arrhythmic Sudden Cardiac Death
    causal_link_type: DIRECT
    description: >-
      A sustained malignant ventricular arrhythmia can precipitate fatal circulatory
      arrest.

- name: Arrhythmic Sudden Cardiac Death
  role: outcome
  biological_scale: ORGANISM
  description: >-
    Sudden cardiac death can be the presenting event, occurring without preceding overt
    heart failure - documented at autopsy by elevated pericardial-fluid NT-proBNP marking
    undiagnosed left ventricular dysfunction.
  evidence:
  - reference: PMID:32939432
    reference_title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cause of death was certified as an early dilated cardiomyopathy (DCM)/dysfunction
      of the left ventricle secondary to DMD
    explanation: >-
      A documented case of sudden death from dystrophin-deficient dilated cardiomyopathy,
      the terminal event this node models.
  downstream:
  - target: Sudden Cardiac Death
    causal_link_type: DIRECT

phenotypes:
- category: Cardiovascular
  name: Dilated Cardiomyopathy
  frequency: VERY_FREQUENT
  description: >-
    The defining and near-universal feature: left ventricular dilation with systolic
    dysfunction, in relative or complete isolation from skeletal myopathy.
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      X-linked dilated cardiomyopathy (XLDCM) is a distinct phenotype of dystrophinopathy
      characterized by preferential cardiac involvement without any overt skeletal myopathy.
    explanation: >-
      States both the defining cardiac phenotype and its isolation from skeletal disease.

- category: Cardiovascular
  name: Congestive Heart Failure
  frequency: VERY_FREQUENT
  description: >-
    The usual presenting syndrome in affected males, typically in adolescence or the
    early twenties.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:8504498
    reference_title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      X-linked cardiomyopathy (XLCM) is a rapidly progressive primary myocardial disorder
      presenting in teenage males as congestive heart failure.
    explanation: >-
      Congestive heart failure as the presenting manifestation in teenage males.

- category: Cardiovascular
  name: Reduced Left Ventricular Ejection Fraction
  description: >-
    The core objective measure of systolic dysfunction, tracked serially and used to
    trigger and titrate heart-failure therapy.
  phenotype_term:
    preferred_term: Reduced left ventricular ejection fraction
    term:
      id: HP:0012664
      label: Reduced left ventricular ejection fraction
  evidence:
  - reference: PMID:40130400
    reference_title: "Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Absolute LVEF% values reduced in both groups ('active': 62.5% ± 5.6% to 53.8% ±
      4.0%; 'placebo': 60.6% ± 4.9% to 50.4% ± 8.5%).
    explanation: >-
      Documents the progressive fall in left ventricular ejection fraction over follow-up
      in dystrophin-deficient cardiomyopathy; measured in a DMD cohort and applied to
      XLDCM as the same dystrophin-deficient cardiomyopathy, hence INDIRECT.

- category: Cardiovascular
  name: Ventricular Arrhythmia
  frequency: FREQUENT
  description: >-
    Emerges as the ventricle dilates and fibroses; a major contributor to mortality and
    sudden death.
  phenotype_term:
    preferred_term: Ventricular arrhythmia
    term:
      id: HP:0004308
      label: Ventricular arrhythmia
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      showed rapidly progressive heart failure and ventricular arrhythmias between 10 and
      20 years old.
    explanation: >-
      Ventricular arrhythmia alongside heart failure in the affected males of the founding
      XLDCM kindred.

- category: Cardiovascular
  name: Sudden Cardiac Death
  description: >-
    Can occur without preceding overt heart failure, sometimes as the presenting event.
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
  evidence:
  - reference: PMID:32939432
    reference_title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we reported a case of 29-year-old man who died suddenly.
    explanation: >-
      A documented sudden death from previously undiagnosed dystrophin-deficient
      cardiomyopathy.

- category: Laboratory
  name: Elevated Creatine Kinase
  frequency: OCCASIONAL
  description: >-
    Serum creatine kinase is variable in XLDCM - it can be markedly elevated but is often
    normal, particularly with exon 45-55 deletions and in later-onset or female cases - so
    unlike in classic Duchenne, a normal CK does not exclude the diagnosis.
  phenotype_term:
    preferred_term: Elevated circulating creatine kinase concentration
    term:
      id: HP:0003236
      label: Elevated circulating creatine kinase concentration
  evidence:
  - reference: PMID:10841222
    reference_title: "Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum CPK levels were increased in 11 of 13 patients.
    explanation: >-
      Creatine phosphokinase was elevated in most, but not all, dystrophin-defect DCM
      patients, consistent with a variable, non-discriminating CK.

- category: Cardiovascular
  name: Dilated Cardiomyopathy in Heterozygous Female Carriers
  description: >-
    Carrier females are not cardiac-silent. About 8% develop dilated cardiomyopathy,
    typically with later onset and milder course than affected males, its risk rising with
    age and tracking skewed X-inactivation - which is why carriers warrant their own
    cardiac surveillance.
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
    onset:
      onset_category: ADULT
  evidence:
  - reference: PMID:32650403
    reference_title: "Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It is known that about 8% of carriers present with dilated cardiomyopathy, though it
      may vary from 0% to 16.7%, depending on if the carrier is classified as having DMD or
      BMD.
    explanation: >-
      Quantifies the carrier-female cardiomyopathy risk and its range across DMD/BMD carrier
      classes.

genetic:
- name: DMD
  gene_term:
    preferred_term: DMD
    term:
      id: hgnc:2928
      label: DMD
  relationship_type: CAUSATIVE
  inheritance:
  - name: X-linked recessive
  notes: >-
    The same gene as Duchenne and Becker muscular dystrophy. XLDCM arises from a specific
    subset of DMD lesions that damage cardiac dystrophin while sparing skeletal muscle:
    (1) deletions of the muscle (M) promoter and first muscle exon at the 5' end, which
    abolish the muscle isoform (the paradigmatic "5' XLDCM"); (2) in-frame deletions in the
    exon 45-55 hotspot, which can present cardiac-predominantly with mild or absent skeletal
    disease; and (3) destabilizing missense variants. The functional consequence is loss or
    destabilization of dystrophin rather than a gain-of-function or dominant-negative effect.
  evidence:
  - reference: PMID:8504498
    reference_title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      XLCM is due to an abnormality within the centromeric half of the dystrophin genomic
      region in heart.
    explanation: >-
      Localizes the causal lesion to the dystrophin (DMD) gene, establishing XLDCM as a
      dystrophinopathy.
  - reference: PMID:18261911
    reference_title: "Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two younger patients diagnosed as having X-linked dilated cardiomyopathy (XLDCM)
      developed congestive heart failure without overt skeletal myopathy.
    explanation: >-
      Documents the exon 45-55 in-frame deletion class producing cardiac-predominant XLDCM
      without skeletal myopathy.

inheritance:
- name: X-linked recessive
  description: >-
    Hemizygous males are affected early and severely; heterozygous carrier females develop
    a milder, later-onset dilated cardiomyopathy, and there is no male-to-male transmission -
    the pedigree signature that distinguishes XLDCM from autosomal dominant familial DCM.
    Manifesting carriers are common, with expressivity governed by skewed X-inactivation.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:3574369
    reference_title: "X-linked dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      X-linked inheritance of dilated cardiomyopathy is suggested in this family by the early
      onset in males, late onset in females, and no evidence of male-to-male transmission.
    explanation: >-
      The original pedigree evidence for X-linked inheritance, including the
      no-male-to-male-transmission clue.
  - reference: PMID:3574369
    reference_title: "X-linked dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The late onset of the disease in females, in contrast to the early onset in hemizygous
      males, is compatible with heterozygosity for the mutant allele.
    explanation: >-
      The manifesting-carrier pattern: later-onset disease in heterozygous females.

has_subtypes:
- name: 5-prime XLDCM
  display_name: 5' muscle-promoter / exon-1 XLDCM
  description: >-
    The paradigmatic, severe class: a deletion of the muscle (M) promoter and first
    muscle exon at the 5' end of DMD abolishes the muscle dystrophin isoform. Skeletal
    muscle is rescued by up-regulating the brain isoform, but the ventricle cannot, so
    the phenotype is a rapidly progressive, often lethal cardiomyopathy in adolescent and
    young-adult males. Standard multi-exon deletion panels can under-detect the isolated
    promoter-region lesion.
  genes:
  - preferred_term: DMD
    term:
      id: hgnc:2928
      label: DMD
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the causative mutation would include a deletion in the region and in exon 1
    explanation: >-
      Documents the 5' muscle-promoter/exon-1 deletion that defines this subtype.
- name: Exon 45-55
  display_name: Exon 45-55 in-frame deletion XLDCM
  description: >-
    An in-frame deletion in the exon 45-55 hotspot presents cardiac-predominantly with
    mild or absent skeletal disease, a more indolent course, and better responsiveness to
    ACE-inhibitor/beta-blocker therapy than the 5' class. Serum CK is frequently normal
    in this subtype.
  genes:
  - preferred_term: DMD
    term:
      id: hgnc:2928
      label: DMD
  evidence:
  - reference: PMID:18261911
    reference_title: "Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two younger patients diagnosed as having X-linked dilated cardiomyopathy (XLDCM)
      developed congestive heart failure without overt skeletal myopathy.
    explanation: >-
      Documents the exon 45-55 in-frame deletion class producing cardiac-predominant XLDCM
      without skeletal myopathy.

prevalence:
- population: Isolated cardiac (skeletal-sparing) XLDCM
  measure_type: UNKNOWN
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population-based prevalence estimate exists for the isolated cardiac XLDCM phenotype,
    which is historically defined by individual pedigrees rather than registries. The
    available numbers are diagnostic yields, not population rates: DMD defects were found in
    6.5% (13/201) of consecutive adult male DCM patients screened by Arbustini et al., and
    3% of a Japanese adult DCM cohort. These are the fraction of "idiopathic" male DCM
    attributable to dystrophin, not the occurrence of XLDCM in the general population, and
    must not be compared with a whole-population prevalence.
  evidence:
  - reference: PMID:10841222
    reference_title: "Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dystrophin defects were identified in 13 of the 201 patients (6.5%, age 16-50).
    explanation: >-
      The diagnostic yield of dystrophin defects among consecutive male DCM patients, quoted
      as a yield and not a population prevalence.

diagnosis:
- name: DMD Molecular Genetic Testing (Deletion/Duplication Analysis then Sequencing)
  description: >-
    XLDCM is confirmed by identifying a pathogenic DMD variant. Multiplex ligation-dependent
    probe amplification (MLPA) or targeted deletion/duplication analysis is the first-tier
    test because most dystrophinopathy lesions are deletions/duplications; full-gene
    sequencing follows to detect the point mutations, small indels, and splice/deep-intronic
    variants that MLPA cannot see.
  evidence:
  - reference: PMID:20301298
    reference_title: "Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      identification of a hemizygous pathogenic variant in DMD on molecular genetic testing
      in a male and of a heterozygous pathogenic variant in DMD on molecular genetic testing
      in a female
    explanation: >-
      GeneReviews states how a dystrophinopathy diagnosis is molecularly established in males
      and in carrier females.
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The definitive diagnosis is defined by the identification of the DMD gene mutations by
      gene analysis such as multiplex-PCR or multiplex ligation dependent probe amplification
      (MLPA).
    explanation: >-
      Names MLPA as the definitive molecular diagnostic method for XLDCM.

- name: Muscle-Promoter / Exon-1-Specific Analysis
  description: >-
    Because the paradigmatic 5' XLDCM lesion is a deletion of the muscle promoter and first
    muscle exon, testing that specifically covers the 5' promoter/exon-1 region is important
    when a cardiac-predominant phenotype with normal or near-normal strength is seen -
    standard multi-exon deletion panels can under-detect an isolated promoter-region lesion.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the causative mutation would include a deletion in the region and in exon 1
    explanation: >-
      Documents the muscle-promoter/exon-1 location of the causative lesion that motivates
      5'-specific testing.

- name: Electrocardiography (Characteristic Dystrophinopathy Pattern)
  description: >-
    A characteristic (though not pathognomonic) ECG pattern - tall R waves with high R/S
    ratio in the right precordial leads and deep lateral/inferior Q waves - is often present,
    sometimes before symptomatic heart failure, and is part of baseline and surveillance
    evaluation.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The electrocardiogram (ECG) in dystrophinopathy shows high R waves (R/S > 1) in the
      right precordial leads (V1-2), deep Q waves in leads I, aVL, and V5-6 or in leads II,
      III, and aVF
    explanation: >-
      The characteristic dystrophinopathy ECG signature used in XLDCM evaluation.

- name: Cardiac Imaging (Echocardiography and Cardiac MRI)
  description: >-
    Echocardiography is the first-line serial modality for left ventricular size and
    function. Cardiac MRI adds late gadolinium enhancement (LGE), the imaging correlate of
    the posterobasal/inferolateral fibrofatty replacement, which can precede overt systolic
    dysfunction on echo.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Echocardiography results include myocardial thickening, wall motion abnormalities,
      enlargement of the left ventricle, and left ventricular systolic or diastolic
      dysfunction
    explanation: >-
      The echocardiographic findings tracked in XLDCM cardiac surveillance.
  - reference: PMID:34429516
    reference_title: "Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Those with elevated cTnI were more likely to have late gadolinium enhancement on
      baseline CMR.
    explanation: >-
      Documents CMR late gadolinium enhancement in a DMD cohort; applied to XLDCM as the
      same dystrophin-deficient cardiomyopathy, hence INDIRECT.

- name: Agents / Circumstances to Avoid (Anesthesia)
  description: >-
    Dystrophinopathy patients are susceptible to malignant-hyperthermia-like reactions;
    succinylcholine and inhalational (volatile) anesthetics should be avoided. This is
    clinically important in XLDCM given that these patients may undergo cardiac surgery or
    heart transplantation.
  evidence:
  - reference: PMID:20301298
    reference_title: "Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      succinylcholine and inhalational anesthetics because of susceptibility to malignant
      hyperthermia or malignant hyperthermia-like reactions
    explanation: >-
      GeneReviews lists succinylcholine and inhalational anesthetics among the
      agents/circumstances to avoid in dystrophinopathy.

biochemical:
- name: NT-proBNP
  presence: INCREASED
  context: >-
    N-terminal pro-B-type natriuretic peptide is the best-validated serum biomarker for
    detecting and tracking systolic dysfunction in dystrophin-deficient cardiomyopathy and
    is the practical analyte for longitudinal follow-up. Elevated pericardial-fluid
    NT-proBNP has also marked previously undiagnosed left ventricular dysfunction at autopsy
    in sudden death.
  biomarker_term:
    preferred_term: NT-proBNP measurement
    term:
      id: NCIT:C96610
      label: N-Terminal ProB-type Natriuretic Peptide Measurement
  evidence:
  - reference: PMID:32939432
    reference_title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      N-terminal-proBNP (NT-proBNP) was a robust laboratory biomarker to diagnose and monitor
      cardiac failure in clinical situations
    explanation: >-
      Establishes NT-proBNP as a validated biomarker for cardiac failure, here applied to
      dystrophin-deficient left ventricular dysfunction.
  - reference: PMID:34429516
    reference_title: "Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NT-proBNP correlated with indexed left ventricular end diastolic and maximum left
      atrial volumes.
    explanation: >-
      NT-proBNP tracked left ventricular and atrial volumes in a DMD cohort; applied to
      XLDCM as the same dystrophin-deficient cardiomyopathy, hence INDIRECT.
  notes: >-
    No XLDCM-specific NT-proBNP reference interval or decision threshold could be cited from
    the fetched sources, so no reference_ranges are recorded. Standard cardiac biomarkers,
    including NT-proBNP, correlate only imperfectly with CMR-defined cardiomyopathy
    progression in this population, so NT-proBNP is a monitoring adjunct rather than a
    stand-alone staging tool.

histopathology:
- name: Absent/Reduced Myocardial Dystrophin on Immunostaining
  description: >-
    Immunohistochemical staining of cardiac (or skeletal) muscle shows absence or reduction
    of dystrophin, confirming the molecular diagnosis even when skeletal strength is normal.
  diagnostic: true
  evidence:
  - reference: PMID:32939432
    reference_title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Total absence of dystrophin was detected by immunohistochemical staining, which
      confirmed DMD.
    explanation: >-
      Absence of dystrophin on immunostaining is the confirmatory histopathologic finding.
- name: Cardiomyocyte Degeneration with Enlarged Heart
  description: >-
    The heart is enlarged (dilated) with disarray and degeneration of cardiomyocytes, the
    tissue correlate of the replacement fibrosis and myocyte loss modeled in the pathograph.
  evidence:
  - reference: PMID:32939432
    reference_title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The heart was enlarged with disarray and degeneration of cardiomyocytes in cardiac
      muscle.
    explanation: >-
      Autopsy histology of the dilated, degenerating dystrophin-deficient myocardium.

progression:
- phase: Classic 5' XLDCM (rapid)
  subtype: 5-prime XLDCM
  age_range: 10-20 years (males)
  notes: >-
    Rapidly progressive; in the original kindred affected males died within 5 to 12 months
    of symptom onset.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      die of heart failure between 10 and 20 years old
    explanation: >-
      The rapid, lethal course of classic XLDCM in males.
- phase: Exon 45-55 deletion (indolent)
  subtype: Exon 45-55
  notes: >-
    Milder, treatment-responsive course with relatively good life expectancy.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      they usually have a good life expectancy
    explanation: >-
      The more indolent prognosis of the exon 45-55 hotspot subtype.

treatments:
- name: Heart Failure Pharmacotherapy (ACE Inhibitor and Beta-Blocker)
  description: >-
    Standard heart-failure guideline-directed medical therapy is the mainstay for the
    dilated cardiomyopathy: an ACE inhibitor, usually combined with a beta-blocker.
    Combination therapy improved left ventricular function relative to ACE-inhibitor
    monotherapy in the dystrophinopathy-cardiomyopathy literature. An important recent
    caveat from the DMD Heart Protection Study long-term follow-up is that starting therapy
    prophylactically (before detectable dysfunction) did not produce a group-mean
    ejection-fraction advantage over starting at first detected dysfunction, though the trial notes
    small numbers and echo insensitivity - so early detection and prompt treatment at first
    dysfunction is the defensible strategy rather than universal prophylaxis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  target_mechanisms:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    treatment_effect: INHIBITS
    description: >-
      Standard neurohormonal-blockade heart-failure therapy acting on the ventricular
      remodeling and failure endpoint rather than on the dystrophin deficit.
    evidence:
    - reference: PMID:40130400
      reference_title: "Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        DMD Care Standards recommend starting angiotensin‐converting enzyme inhibitor (ACEi)
        medication empirically no later than the age of 10 years
      explanation: >-
        The standard-of-care recommendation to treat dystrophin-deficient cardiomyopathy with
        an ACE inhibitor.
  evidence:
  - reference: PMID:40130400
    reference_title: "Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While some patients may have benefited from 'early' (active) as opposed to 'delayed'
      (placebo) initiation of perindopril and bisoprolol, group-mean ventricular function did
      not differ between study arms after 60 months.
    explanation: >-
      The prophylaxis-versus-treat-at-detection nuance that qualifies how this therapy is
      timed.

- name: Angiotensin Receptor Blocker (Losartan) as ACE-Inhibitor Alternative
  description: >-
    An angiotensin receptor blocker such as losartan is an accepted alternative to an ACE
    inhibitor; a randomized double-blind trial of lisinopril versus losartan in
    dystrophin-deficient cardiomyopathy found both effective without establishing superiority of either.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: angiotensin II receptor antagonist
      term:
        id: NCIT:C66930
        label: Angiotensin II Receptor Antagonist
    - preferred_term: losartan
      term:
        id: CHEBI:6541
        label: losartan
  target_mechanisms:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    treatment_effect: INHIBITS
    description: >-
      Renin-angiotensin blockade as an alternative to ACE inhibition for the failing
      ventricle.
  evidence:
  - reference: PMID:24459612
    reference_title: "A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is no therapeutic difference in EF improvement between lisinopril and losartan
      over the one-year duration for treatment of boys with DMD-related CM.
    explanation: >-
      The randomized trial establishing losartan (ARB) as equivalent to lisinopril (ACE
      inhibitor) for dystrophin-deficient cardiomyopathy, supporting the ARB as an alternative.

- name: Heart Transplantation
  description: >-
    The only curative option for end-stage dystrophin-deficient heart failure refractory to
    medical therapy. XLDCM is a favorable transplant setting precisely because skeletal and
    respiratory function is typically preserved - the comorbidity that complicates transplant
    candidacy in classic Duchenne is largely absent here - and post-transplant outcomes are
    comparable to non-dystrophinopathy recipients.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: cardiac transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    treatment_effect: BYPASSES
    description: >-
      Replaces the failing organ rather than acting on the dystrophin deficit, which persists
      in the remaining tissues.
    evidence:
    - reference: PMID:28580208
      reference_title: "Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Heart transplantation (HT) is the only curative therapy for patients with
        dystrophinopathic end-stage heart failure who remain symptomatic despite an optimal
        medical therapy.
      explanation: >-
        States transplantation as the only curative option for end-stage dystrophinopathic
        cardiomyopathy.
  evidence:
  - reference: PMID:28580208
    reference_title: "Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      heart transplantation is a safe and effective treatment for selected patients with
      end-stage DCM.
    explanation: >-
      The authors' conclusion supporting transplantation in selected dystrophinopathic DCM
      patients.
  - reference: PMID:20301298
    reference_title: "Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      cardiac transplantation is offered to persons with severe dilated cardiomyopathy and
      BMD with limited or no clinical evidence of skeletal muscle disease
    explanation: >-
      GeneReviews states that transplantation is offered when skeletal muscle disease is
      limited or absent - precisely the XLDCM situation that makes it a favorable candidate.

- name: Cardiac Surveillance (Including Carrier Females)
  description: >-
    Because subclinical cardiac dysfunction precedes symptoms and skeletal severity does not
    predict cardiac involvement, baseline and serial cardiac evaluation (ECG, echocardiography,
    and cardiac MRI for late gadolinium enhancement) is standard from diagnosis in affected
    individuals. Heterozygous carrier females need surveillance too, given their real,
    X-inactivation-dependent cardiomyopathy risk.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:32650403
    reference_title: "Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cardiac symptoms are particularly prevalent in female dystrophin mutation carriers,
      affecting about 8% of this population with dilated cardiomyopathy (DCM) as a common
      presentation
    explanation: >-
      The carrier cardiac risk that justifies extending surveillance to heterozygous females.
  - reference: PMID:20301298
    reference_title: "Dystrophinopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      For heterozygous females: cardiac evaluation at least once after the teenage years
    explanation: >-
      GeneReviews' explicit surveillance recommendation for heterozygous carrier females.

- name: Device Therapy (ICD and Cardiac Resynchronization Therapy)
  description: >-
    For advanced disease, an implantable cardioverter-defibrillator addresses the ventricular
    arrhythmia / sudden-death risk, and cardiac resynchronization therapy (biventricular
    pacing) is used when heart failure is complicated by ventricular dyssynchrony.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: cardiac resynchronization therapy device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Ventricular Arrhythmogenesis
    treatment_effect: INHIBITS
    description: >-
      Device therapy targets the arrhythmic substrate and dyssynchronous failure rather than
      the dystrophin deficit.
  evidence:
  - reference: PMID:26066469
    reference_title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      cardiac resynchronization therapy (biventricular pacing), is appropriate for cases of
      heart failure with associated ventricular dyssynchrony
    explanation: >-
      The review's statement of CRT indication in dystrophinopathy cardiomyopathy with
      ventricular dyssynchrony.

animal_models:
- name: mdx mouse
  species: Mouse
  genotype: Dmd (mdx) dystrophin-null point mutation
  publication: PMID:30281092
  description: >-
    The standard, most widely used DMD mouse model. It develops a dilated cardiomyopathy
    with decreased fractional shortening, but the cardiac phenotype is mild and late-onset
    relative to human disease - a recognized model limitation.
  modeled_mechanisms:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Reproduces dystrophin-deficient dilated cardiomyopathy but only mildly and late,
      under-representing the severity and tempo of the human ventricular failure.
    limitations: >-
      Standard mouse models do not recapitulate all aspects of human disease pathology and
      exhibit only a mild cardiac phenotype; they also carry combined skeletal-plus-cardiac
      dystrophin loss rather than the cardiac-selective XLDCM lesion.
    evidence:
    - reference: PMID:30281092
      reference_title: "Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Several mouse models have been developed to study molecular and pathological
        consequences of dystrophin deficiency, but do not recapitulate all aspects of human
        disease pathology and exhibit a mild cardiac phenotype.
      explanation: >-
        States the mdx/mouse cardiac-phenotype limitation directly.
- name: Cmah-/-;mdx mouse
  species: Mouse
  genotype: Cmah-null on mdx dystrophin-null background (Cmah-/-;mdx)
  publication: PMID:30281092
  description: >-
    An enhanced double-knockout model in which loss of CMP-sialic acid hydroxylase on the
    mdx background accelerates the cardiac phenotype toward the human course, used to
    evaluate cardiac-directed DMD therapeutics.
  modeled_mechanisms:
  - target: Left Ventricular Dilation and Systolic Heart Failure
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Displays earlier ventricular functional deterioration than standard mdx, better
      approximating the human cardiac course.
    limitations: >-
      The acceleration is engineered through a Cmah-null background rather than the human
      isoform-topography mechanism, and the model is not skeletal-sparing, so it does not
      reproduce the cardiac-selective XLDCM phenotype.
    readouts:
    - name: Right ventricular ejection fraction and stroke volume
      target: Left Ventricular Dilation and Systolic Heart Failure
      direction: DECREASED
      interpretation: >-
        Earlier decline in ventricular function than in standard mdx, the functional
        correlate of the accelerated cardiomyopathy.
      evidence:
      - reference: PMID:30281092
        reference_title: "Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          reduction in right ventricle (RV) ejection fraction and stroke volume (SV) at 12
          weeks of age
        explanation: >-
          The measured ventricular-function deficit in this model.
    evidence:
    - reference: PMID:30281092
      reference_title: "Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        have an accelerated cardiac phenotype compared to the established mdx model
      explanation: >-
        Establishes the accelerated cardiac phenotype that makes this an informative cardiac
        model.
- name: Golden Retriever Muscular Dystrophy (GRMD) dog
  species: Dog
  genotype: DMD splice-site mutation causing exon skipping and an out-of-frame transcript
  publication: PMID:28526070
  description: >-
    A naturally occurring, genetically homologous canine dystrophinopathy whose more severe,
    progressive clinical course aligns better with human DMD than rodent models do, used as a
    translational large-animal model including for cardiac studies.
  modeled_mechanisms:
  - target: Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the dystrophin-loss membrane-fragility-and-necrosis mechanism in a
      large-animal system with a human-like progressive course.
    limitations: >-
      GRMD models the combined skeletal-plus-cardiac dystrophinopathy rather than an isolated
      cardiac-selective analog of XLDCM, and cost/availability limit its use.
    evidence:
    - reference: PMID:28526070
      reference_title: "The golden retriever model of Duchenne muscular dystrophy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The absence of dystrophin leads to myofiber membrane fragility and necrosis, with
        eventual muscle atrophy and contractures.
      explanation: >-
        States the membrane-fragility-and-necrosis mechanism this model recapitulates.
  evidence:
  - reference: PMID:28526070
    reference_title: "The golden retriever model of Duchenne muscular dystrophy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Because the GRMD clinical syndrome is more severe than in mice, better aligning with the
      progressive course of DMD, canine studies may translate better to humans.
    explanation: >-
      The translational rationale for using GRMD as a large-animal dystrophinopathy model.

discussions:
- discussion_id: xldcm_cardiac_selective_model_gap
  prompt: >-
    Does any available model reproduce the ventricle-selective, skeletal-sparing dystrophin
    loss that defines XLDCM, or do all models capture only the combined
    skeletal-plus-cardiac dystrophinopathy?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Ventricle-Selective Loss of Dystrophin
  rationale: >-
    The node that makes XLDCM a distinct entity is the ventricle-selective loss of dystrophin
    driven by failed brain-isoform compensation in the human ventricle. Existing models do not
    reproduce this selectivity: standard mdx mice show only a mild, late cardiac phenotype;
    enhanced backgrounds (Cmah-null) and large-animal canine models accelerate or better
    match the course but carry combined skeletal-plus-cardiac dystrophin loss. The
    isoform-topography mechanism therefore rests on human autopsy/explant tissue (Neri 2012),
    and translational validity of model-derived cardiac findings to the cardiac-selective
    human phenotype remains the open question - so cross-model agreement should be judged
    mechanism by mechanism rather than treating a mild or combined-phenotype model as
    representative.
  proposed_experiments:
  - experiment_id: exp_xldcm_ventricle_selective_model
    name: Engineered ventricle-selective 5' DMD-isoform model with human-relevant isoform readouts
    description: >-
      Build a model (e.g., human iPSC-derived ventricular cardiomyocytes or an animal line)
      carrying the 5' muscle-promoter/exon-1 lesion, and measure brain- versus muscle-isoform
      dystrophin transcripts and ventricular dysfunction, testing whether the human
      isoform-compensation-failure mechanism is reproduced in ventricle without skeletal
      rescue confounders.
  evidence:
  - reference: PMID:30281092
    reference_title: "Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Several mouse models have been developed to study molecular and pathological
      consequences of dystrophin deficiency, but do not recapitulate all aspects of human
      disease pathology and exhibit a mild cardiac phenotype.
    explanation: >-
      Direct evidence that standard mouse models under-represent the human cardiac phenotype,
      the mismatch this discussion records.

notes: >-
  Curated from a Claude Code deep-research report
  (research/X-linked_Dilated_Cardiomyopathy-deep-research-claude_code.md; 18 web searches,
  45 citations), with every cited reference independently fetched and quoted from its cached
  abstract or full text.

  Named-entity note: XLDCM (dystrophin/DMD, dilated) must be kept distinct from the other
  X-linked cardiomyopathies the deep-research report flagged as differentials - Barth syndrome
  (TAZ, DCM/LVNC with 3-methylglutaconic aciduria and neutropenia), Danon disease (LAMP2,
  predominantly hypertrophic), and X-linked Emery-Dreifuss muscular dystrophy (EMD). None of
  those share the DMD gene, and this entry cites only DMD/dystrophin sources.

  Two PMIDs supplied to the curator as candidate anchors were verified against the primary
  literature and found to be WRONG, so were not used: PMID:8281153 (proposed for "Towbin 1993")
  resolves to an NF-kappa B gene paper, and PMID:8302331 (proposed for "Muntoni 1993") resolves
  to a non-Hodgkin lymphoma model. The correct primary references are Towbin 1993 (PMID:8504498,
  Circulation, the Xp21 linkage study) and Muntoni 1993 (PMID:8361506, NEJM, the 5'
  muscle-promoter deletion). Muntoni's NEJM "brief report" has no structured abstract in the PubMed
  cache, so the 5' isoform-compensation mechanism is evidenced here from Neri et al. 2012
  (PMID:22455600), which directly maps the ventricular absence of the brain isoform, rather than
  from a Muntoni snippet.

  Conformance to cardiomyopathy_maladaptive_remodeling is claimed at the insult node
  (Sarcolemmal Fragility and Contraction-Induced Cardiomyocyte Injury -> Primary Cardiomyocyte
  Insult) and the outcome node (Left Ventricular Dilation and Systolic Heart Failure ->
  Structural Cardiac Impairment and Heart Failure), following the pattern used in Becker Muscular
  Dystrophy; the module's intervening neurohormonal/remodeling nodes are not separately claimed
  because the references read for this entry do not evidence those specific steps in XLDCM.

  Several mechanistic and treatment statements are supported by review-class sources
  (evidence_source OTHER: the XLDCM cardiospecific review PMID:26066469, the
  DGC-mechanotransduction review PMID:36168044, the calcium-handling review PMID:32075145, the
  carrier-females review PMID:32650403, and the transplant series PMID:28580208), because
  primary human tissue for this rare, lethal phenotype is scarce; the founding pedigree and
  linkage/isoform-mechanism claims rest on primary sources (PMID:3574369, PMID:8504498,
  PMID:22455600).

references:
- reference: PMID:3574369
  title: "X-linked dilated cardiomyopathy."
- reference: PMID:8504498
  title: "X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus."
- reference: PMID:8361506
  title: "Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy."
- reference: PMID:22455600
  title: "The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy."
- reference: PMID:26066469
  title: "X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy."
- reference: PMID:36168044
  title: "The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction."
- reference: PMID:32075145
  title: "Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies."
- reference: PMID:18261911
  title: "Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene."
- reference: PMID:10841222
  title: "Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy."
- reference: PMID:32650403
  title: "Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies."
- reference: PMID:32939432
  title: "Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report."
- reference: PMID:28580208
  title: "Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series."
- reference: PMID:40130400
  title: "Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol."
- reference: PMID:24459612
  title: "A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy."
- reference: PMID:34429516
  title: "Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies."
- reference: PMID:30281092
  title: "Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment."
- reference: PMID:28526070
  title: "The golden retriever model of Duchenne muscular dystrophy."
- reference: PMID:20301298
  title: "Dystrophinopathies."
  tags:
  - GeneReviews
📚

References & Deep Research

References

18
PMID:3574369
X-linked dilated cardiomyopathy.
No top-level findings curated for this source.
PMID:8504498
X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus.
No top-level findings curated for this source.
PMID:8361506
Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy.
No top-level findings curated for this source.
PMID:22455600
The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5' X-linked dilated cardiomyopathy.
No top-level findings curated for this source.
PMID:26066469
X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy.
No top-level findings curated for this source.
PMID:36168044
The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction.
No top-level findings curated for this source.
PMID:32075145
Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies.
No top-level findings curated for this source.
PMID:18261911
Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene.
No top-level findings curated for this source.
PMID:10841222
Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy.
No top-level findings curated for this source.
PMID:32650403
Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies.
No top-level findings curated for this source.
PMID:32939432
Sudden cardiac death of Duchenne muscular dystrophy with NT-proBNP in pericardial fluid as a useful biomarker for diagnosis of the cause of death: a case report.
No top-level findings curated for this source.
PMID:28580208
Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series.
No top-level findings curated for this source.
PMID:40130400
Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol.
No top-level findings curated for this source.
PMID:24459612
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
No top-level findings curated for this source.
PMID:34429516
Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.
No top-level findings curated for this source.
PMID:30281092
Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
No top-level findings curated for this source.
PMID:28526070
The golden retriever model of Duchenne muscular dystrophy.
No top-level findings curated for this source.
PMID:20301298
Dystrophinopathies.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
X-Linked Dilated Cardiomyopathy: Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 45 citations 2026-09-03T15:02:20.575829

X-Linked Dilated Cardiomyopathy: Comprehensive Research Report

1. Disease Information

Overview

X-linked dilated cardiomyopathy (XLDCM, also abbreviated XLCM) is a cardiospecific phenotype of dystrophinopathy — the same gene (DMD, encoding dystrophin) that causes Duchenne (DMD) and Becker (BMD) muscular dystrophy, but expressed almost exclusively as heart muscle disease with minimal or absent skeletal myopathy. It was first delineated as a distinct clinical entity by Berko and Swift (1987), who described a five-generation kindred with 11 young males exhibiting rapidly progressive dilated cardiomyopathy (DCM) and congestive heart failure with onset between ages 15–21, and death within 5–12 months of symptom onset; carrier mothers developed a milder, later-onset (40s) DCM (N Engl J Med 1987;316(19):1186-91, PMID:3574369). Molecular linkage of this phenotype to the centromeric portion of the dystrophin (DMD) locus at Xp21 was established by Towbin et al. (combined maximum LOD score +4.33) (PMID:8504498).

Mechanistically, XLDCM is now understood as one end of a phenotypic continuum produced by DMD gene mutations — ranging from classic Duchenne muscular dystrophy (severe, out-of-frame, both skeletal and cardiac muscle affected) through Becker muscular dystrophy (milder, in-frame) to "cardiac-only" XLDCM, in which mutations selectively abolish or destabilize the cardiac (M) dystrophin isoform while sparing skeletal muscle function, often through compensatory up-regulation of brain (B) and Purkinje (P) dystrophin isoforms in skeletal muscle but not in the ventricular myocardium (Muntoni et al., PMID:8361506; Neri et al. 2012, PMID:22455600) — see [Mechanism, §6].

Key Identifiers

System Identifier
OMIM #302045 — Cardiomyopathy, Dilated, 3B (CMD3B); phenotype MIM caused by DMD mutations, Xp21.2-p21.1 (omim.org/entry/302045)
Gene (OMIM) DMD, †300377
HGNC DMD HGNC:2928
Inheritance X-linked (recessive in classic form; manifesting carriers common)
ICD-10-CM I42.8 (Other cardiomyopathies) — no dedicated XLDCM code; some coders use G71.0 (muscular dystrophy) as a cross-reference when dystrophinopathy is documented
MeSH Cardiomyopathy, Dilated (D002311); cross-referenced with Muscular Dystrophy, Duchenne (D009136)
Orphanet XLDCM is not separately coded; it is discussed as a phenotype within the dystrophinopathy spectrum (ORPHA:98896 Duchenne muscular dystrophy / ORPHA:98895 Becker muscular dystrophy)
MONDO Not confirmed via a direct database lookup in this research session — flag this as unresolved; the entity is likely represented indirectly through MONDO's dystrophinopathy/DCM hierarchy rather than as a standalone term. Verify directly against the MONDO release before curation.

Synonyms

X-linked dilated cardiomyopathy; XLCM; XLDCM; dystrophin-associated dilated cardiomyopathy; cardiac-specific dystrophinopathy; "5′ X-linked dilated cardiomyopathy" (for the promoter/exon-1 subtype).

Data provenance note

Much of the foundational literature (Berko & Swift 1987; Towbin 1993; Muntoni 1993) derives from individual pedigree/family case series rather than large aggregated disease-level registries — XLDCM as a discrete label is a rare, historically pedigree-defined entity. More recent aggregate data on DMD-associated DCM prevalence come from cohort screening studies of idiopathic/familial DCM populations (e.g., Italy, Japan, USA cohorts cited below), which are aggregated clinical-genetic studies, not single-patient reports.

2. Etiology

Disease Causal Factor

XLDCM is monogenic, caused by pathogenic variants in DMD (dystrophin), Xp21.2-p21.1, the largest known human gene (~2.2 Mb, 79 exons). There is no meaningful environmental or infectious causal contribution to the primary disease process, though secondary modifiers exist (below).

Genetic Risk Factors

  • Causal variants: A specific subset of DMD mutations produces the cardiac-selective phenotype rather than classic DMD/BMD (detailed in §4 and §6). These cluster in:
  • The muscle-specific promoter and exon 1 (5′ end) — deletions here abolish transcription of the muscle dystrophin isoform (Muntoni et al. 1993, PMID:8361506).
  • Exons 45–55 ("hot-spot" deletion region) — large in-frame or borderline deletions here are disproportionately associated with cardiac-predominant phenotypes with mild/absent skeletal disease and comparatively good response to standard heart-failure therapy (Nakamura et al. 2008, PMID:18261911).
  • Missense variants in the N-terminal actin-binding domain (e.g., K18N in exon 2) and elsewhere (e.g., F3228L in exon 67) that destabilize dystrophin without abolishing production.
  • Splice-site and retrotransposon-insertion mutations (intron 1 splice mutations; L1 element insertions in exon 1 producing frameshift; Yoshida et al. 1993/1998, PMID:8413368, PMID:9618170).
  • Modifier genes: Utrophin (autosomal paralog of dystrophin) up-regulation partially compensates in skeletal but not cardiac muscle in some genotypes; polymorphisms in genes such as LTBP4, SPP1 (osteopontin), and ACTN3 are established modifiers of skeletal disease severity in DMD/BMD and are plausible (though less well-studied) modifiers of the cardiac phenotype.
  • Susceptibility in DMD carrier females: Skewed X-chromosome inactivation is the principal genetic risk factor for "manifesting carrier" cardiomyopathy — a higher proportion of X-inactivation of the wild-type allele in cardiomyocytes correlates with more severe cardiac phenotype (source: PMC7397028, review "Cardiac Involvement in Dystrophin-Deficient Females," 2020).

Environmental / Lifestyle Risk Factors

  • Exercise / mechanical stress ("use hypothesis"): In dystrophin-deficient (mdx) mice, physical/exercise stress accelerates myocardial damage, supporting a "second hit" mechanotransduction-stress model layered on top of the genetic lesion (Nakamura et al., cited in PMC4491663 review).
  • Age is a major modifier: cardiomyopathy penetrance in male dystrophinopathy patients is essentially 100% by young adulthood; carrier females typically manifest later (40s–50s).
  • Sex is intrinsic to X-linked inheritance: males are hemizygous and more severely/uniformly affected; females are heterozygous carriers with variable, X-inactivation-dependent expressivity.
  • No specific toxin, occupational, dietary, or infectious risk factor is established for the primary genetic lesion; standard DCM risk modifiers (e.g., alcohol, anthracycline exposure) could theoretically exacerbate cardiac dysfunction in a mutation carrier but are not disease-specific.

Protective Factors

  • In-frame, exon 45–55 deletions are relatively "protective" against skeletal myopathy compared with out-of-frame mutations (reading-frame rule; see §4), and this same mutation class is associated with better long-term prognosis and more favorable response to ACE inhibitor/beta-blocker therapy in the cardiac-only phenotype (PMC4491663).
  • Early ACE-inhibitor and beta-blocker initiation functions as a clinical/pharmacological protective intervention rather than a genetic/environmental one (see §12).
  • No validated protective genetic variant (e.g., a modifier allele that prevents cardiomyopathy in a dystrophin-null background) has been established in humans; utrophin up-regulation is protective in model systems (§15) but is not a naturally occurring human protective polymorphism of established effect size.

Gene-Environment Interactions

The clearest documented gene-environment interaction is the exercise/mechanical-stress interaction in dystrophin-deficient cardiac muscle: the DGC's mechanotransduction role means that mechanical loading (physical exertion) interacts with the underlying membrane fragility to accelerate cardiomyocyte injury — demonstrated in mdx mice and inferred clinically (PMC4491663; PMC9515174, "The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction," Commun Biol 2022, PMID:36168044).

3. Phenotypes

XLDCM's defining phenotypic feature is a cardiac phenotype occurring in relative or complete isolation from skeletal myopathy — this is what separates it clinically from typical DMD/BMD cardiomyopathy, which occurs against a background of overt limb-girdle weakness.

Cardiac phenotypes

Phenotype HPO term (suggested) Onset/Course Frequency notes
Congestive heart failure HP:0001635 (Congestive heart failure) Typically ages 10–20 in classic XLDCM pedigrees; can present later (40s–50s) in manifesting carrier females Presenting feature in most reported cases
Dilated cardiomyopathy (left ventricular dilation/dysfunction) HP:0001644 (Dilated cardiomyopathy) Progressive; rapid deterioration in classic pedigrees (symptom-to-death interval 5–12 months in the original Berko & Swift kindred) Defining feature
Reduced left ventricular ejection fraction HP:0012664 (Ejection fraction reduced) Progressive Core diagnostic feature
Ventricular arrhythmia HP:0004308 (Ventricular arrhythmia) Emerges with disease progression; a major cause of sudden death Frequent, contributes to mortality
Cardiac conduction abnormality HP:0011675 (Arrhythmia) Variable ECG often abnormal before symptoms
Elevated R/S ratio in V1–V2 on ECG (procedural finding, not a standard HPO term) Present early, sometimes pre-symptomatic Characteristic ECG signature described across dystrophinopathy cardiac literature
Deep Q waves in lateral/inferior leads (procedural finding) Early Characteristic
Sudden cardiac death HP:0001645 (Sudden death) Can occur without preceding overt heart failure Documented, including with post-mortem NT-proBNP elevation in pericardial fluid used diagnostically (PMC7476613, PMID:32939432)

Skeletal/muscular phenotypes (minimal or absent by definition)

  • Exertional myalgia, calf pseudohypertrophy (HP:0003707), and mildly elevated CK can occur even in "pure" XLDCM, and some patients show subclinical myopathic changes on biopsy despite normal strength — the "cardiospecific" label describes the dominant/presenting phenotype, not necessarily complete absence of any skeletal-muscle molecular abnormality.
  • Frank proximal weakness, Gowers sign, and progressive ambulatory loss (hallmarks of DMD) are absent by definition in classic XLDCM; when present, the case is better classified as DMD/BMD-associated cardiomyopathy rather than "pure" XLDCM.

Laboratory abnormalities

  • Creatine kinase (CK): Ranges from normal (notably in exon 45–55 hotspot deletions and in some late-onset/female cases) to markedly elevated (>2,500 IU/L, versus normal 62–287 IU/L) — CK is not reliably discriminating for XLDCM the way it is for DMD.
  • NT-proBNP: The most useful serum biomarker for tracking systolic dysfunction; an NT-proBNP threshold >200 pg/mL discriminated severe systolic dysfunction with 90.5% sensitivity / 90.9% specificity in a DMD cardiomyopathy cohort, and NT-proBNP (unlike BNP or troponin) was independently associated with mortality (Circ Heart Fail 2024, ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.123.010700).
  • Troponin I: Transient elevations ("troponin leak") occur even in asymptomatic dystrophinopathy patients and correlate with late gadolinium enhancement (LGE) on cardiac MRI, but standard cardiac biomarkers overall correlate poorly with CMR-defined cardiomyopathy progression (PMC8866537, PMID:34429516) — an important caveat for using troponin as a toxicity/monitoring marker in clinical trials.

Age of onset, severity, progression, frequency

  • Onset: Classic XLDCM — adolescence to early adulthood (10–20 years) in males; 4th–5th decade in manifesting female carriers. Later-onset (>50 years) cases with normal CK have also been reported (case report cited in PMC4491663).
  • Severity/progression: Highly genotype-dependent. Promoter/exon-1 mutations (5′ XLDCM) tend toward rapid, severe progression; exons 45–55 deletions tend toward a milder course with better pharmacologic responsiveness.
  • Frequency of DMD mutations among DCM cohorts (i.e., how often "idiopathic"/familial DCM turns out to be dystrophin-related): Italy 13/201 (6.5%) (Arbustini et al. 2000, PMID:10841222); Japan 3/99 (3%) (Shimizu et al. 2005, PMID:15671604); USA pediatric cohort 3/22 (13.6%) (source: PMC4491663 synthesis).

Quality of life impact

No disease-specific QOL instrument for XLDCM was identified in this search; QOL burden is inferred from the DMD/BMD cardiomyopathy literature and general pediatric heart-failure QOL data (PedsQL, EQ-5D), where progressive heart failure, arrhythmia burden, and — particularly for classic XLDCM — a compressed, unpredictable disease course (death within months of symptom onset in the original kindred) impose severe QOL and psychosocial burden on both patients and, given the late-onset carrier phenotype, mothers as well.

4. Genetic/Molecular Information

Causal Gene

  • DMD (dystrophin), Xp21.2-p21.1; HGNC:2928; OMIM gene *300377. The gene spans ~2.2 Mb (largest in the human genome), with multiple tissue-specific promoters driving distinct transcripts/isoforms (full-length muscle [Dp427m], brain [Dp427c], and Purkinje [Dp427p] isoforms from the 5′ end, plus shorter internal-promoter isoforms Dp260, Dp140, Dp116, Dp71).

Pathogenic Variant Classes Specific to XLDCM

  1. Muscle-promoter/exon 1 deletions ("5′ XLDCM") — abolish Dp427m (muscle) transcription while leaving Dp427c (brain/Purkinje) isoform loci intact; skeletal muscle compensates by up-regulating the brain isoform, but the ventricular myocardium does not, because Dp427c is normally expressed there only in atria and conduction tissue, not ventricles (Muntoni et al. 1993, PMID:8361506; mechanistic confirmation in Neri et al. 2012, PMID:22455600, "The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5′ X-linked dilated cardiomyopathy," BMC Med Genet).
  2. Exons 45–55 hotspot deletions — the single most common deletion region in dystrophinopathy generally; in-frame deletions here can produce a cardiac-predominant phenotype with mild/absent skeletal involvement (Nakamura et al. 2008, PMID:18261911).
  3. Missense variants in the actin-binding domain (e.g., p.Lys18Asn in exon 2) or elsewhere (e.g., p.Phe3228Leu in exon 67) that destabilize the protein without eliminating expression.
  4. A recently reported de novo missense variant, p.Asp3368Gly, associated with XLDCM plus skeletal myopathy, characterized with clinical and in silico structural analysis (PMC10931831, 2024).
  5. Splice-site mutations (e.g., intron 1, IVS5+1 in intron 5) and retrotransposon (L1) insertions in exon 1 causing frameshift (Yoshida et al., PMID:8413368, PMID:9618170).
  6. A recurrent frameshift, c.3779_3785delCTTTGGAinsGG in exon 27, reported in the XLDCM literature.

Reading-Frame Rule

The classic dystrophinopathy genotype-phenotype correlate: out-of-frame deletions/duplications disrupt the reading frame and produce a truncated, non-functional protein → severe DMD phenotype; in-frame mutations preserve the reading frame, yielding a partially functional, internally truncated protein → milder BMD phenotype. XLDCM occupies a distinctive niche within (and sometimes outside) this rule — cardiac-restricted phenotypes can arise from in-frame mutations in regions dispensable for skeletal-muscle function but critical for cardiac-specific dystrophin-binding partner interactions (e.g., nNOS binding via the rod-domain repeats 16–17), or from mutations that differentially affect tissue-specific isoform/promoter usage rather than obeying the frame rule at all.

Variant Classification and Population Frequency

  • ClinVar/ACMG classification of specific XLDCM-associated variants should be verified per-variant; the deletions and point mutations cited above are generally classified pathogenic/likely pathogenic in the literature reporting them, based on segregation with the cardiac phenotype and (for deletions) reading-frame/isoform-disruption logic.
  • Population allele frequency in gnomAD for large structural DMD deletions is expected to be essentially zero given the severity of the classic phenotype; specific missense variants (e.g., K18N, F3228L, D3368G) should be checked individually against gnomAD — this was not independently verified via database query in this session and should be confirmed before curation.
  • Somatic vs. germline: XLDCM-causing variants are germline; there is no established somatic-mosaicism disease model for this entity beyond the general phenomenon of germline/somatic mosaicism recognized across dystrophinopathies (relevant to recurrence-risk counseling).

Functional Consequences

Predominantly loss of function (null/near-null muscle-isoform expression from promoter/exon-1 mutations) or partial loss of function / destabilization (missense variants, in-frame deletions) rather than gain-of-function or dominant-negative mechanisms — consistent with dystrophin's structural/scaffolding role (see §6).

Modifier Genes

No XLDCM-specific modifier gene has been rigorously validated in this literature search; general DMD/BMD skeletal-muscle severity modifiers (LTBP4, SPP1/osteopontin, ACTN3) are candidates for cardiac modifier study but are not established as such.

Chromosomal Abnormalities

XLDCM is caused by intragenic DMD deletions/duplications/point mutations rather than large chromosomal rearrangements; contiguous gene deletion syndromes involving DMD plus neighboring genes (e.g., glycerol kinase deficiency, congenital adrenal hypoplasia) produce a different, syndromic phenotype and are not the XLDCM entity per se.

Epigenetics

No XLDCM-specific epigenetic (DNA methylation/histone) mechanism was identified in this search; the isoform-switching mechanism (§6) is transcriptional/promoter-based rather than classically epigenetic, though promoter-region deletions functionally abolish the regulatory element itself rather than altering its methylation state.

5. Environmental Information

XLDCM is a monogenic disorder with no established primary environmental, toxic, or infectious causal agent. The relevant environmental modifiers are:

  • Physical exertion / mechanical loading: proposed as a "second hit" that accelerates myocardial injury on a dystrophin-null background (the "use hypothesis," supported in mdx mouse exercise studies cited in PMC4491663). This has direct clinical translation — activity restriction is often part of dystrophinopathy cardiac management guidance, though formal evidence specific to XLDCM (as opposed to DMD generally) is limited.
  • Cardiotoxic exposures (e.g., anthracyclines, alcohol) are not disease-specific risk factors but would be expected to compound dysfunction in a mutation carrier, by general cardiology principles; no XLDCM-specific literature on this interaction was found.
  • Infectious agents: no infectious trigger or myocarditis-superimposition literature specific to XLDCM was identified in this search (in contrast to some other DCM etiologies, e.g., viral myocarditis-triggered DCM).

6. Mechanism / Pathophysiology

Causal chain (ordered, from initiating lesion to clinical manifestation)

  1. A germline pathogenic DMD variant (promoter/exon-1 deletion, hotspot exon 45–55 deletion, or destabilizing missense/splice variant) disrupts production, stability, or tissue-specific isoform expression of dystrophin — demonstrated directly. (Muntoni 1993, PMID:8361506; Towbin 1993, PMID:8504498)
  2. For promoter/exon-1 (5′) mutations specifically, this abolishes transcription of the muscle (Dp427m) dystrophin isoform. In skeletal muscle, this loss is compensated by transcriptional up-regulation of the brain (Dp427c) and Purkinje (Dp427p) isoforms from intact downstream promoters — demonstrated. (Muntoni 1993)
  3. In ventricular myocardium, the brain isoform is not normally expressed (it is confined to atria and cardiac conduction tissue in the healthy heart), so no compensatory isoform is available — this step is the direct explanation for cardiac-selective vulnerability and is demonstrated by isoform-expression mapping of healthy human hearts. (Neri et al. 2012, PMID:22455600) → leads to unmitigated loss of functional dystrophin specifically in ventricular cardiomyocytes.
  4. Loss (or destabilization) of dystrophin disrupts the dystrophin-glycoprotein complex (DGC), which normally links the intracellular actin cytoskeleton through the sarcolemma to the extracellular matrix (laminin-α2) — demonstrated structurally and biochemically. (PMC9515174, Commun Biol 2022, PMID:36168044) → results in loss of sarcolemmal mechanical integrity and disrupted mechanotransduction signaling.
  5. A structurally compromised sarcolemma is mechanically fragile under contractile/mechanical stress — demonstrated in cell and animal models — leading to microtears in the cardiomyocyte membrane during normal cardiac cycling, exacerbated by physical exertion (the "use hypothesis"; mdx mouse exercise data cited in PMC4491663).
  6. Membrane microdamage causes pathological calcium influx and intracellular calcium mishandling/overload — demonstrated mechanistically in cardiomyocyte models (PMC7074327, "Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy") → results in activation of calcium-dependent proteases (calpains), mitochondrial calcium overload, and downstream cell-death signaling.
  7. Chronic calcium dysregulation and membrane injury drive cardiomyocyte necrosis and apoptosis, with secondary replacement fibrosis and fatty infiltration, characteristically beginning in the left ventricular posterobasal/inferolateral wall — demonstrated on myocardial biopsy and cardiac MRI (late gadolinium enhancement) across dystrophinopathy cardiomyopathy studies, and specifically noted for XLDCM in the PMC4491663 synthesis.
  8. Progressive myocyte loss and fibrotic replacement impair contractile function and electrical conduction, leading to progressive left ventricular dilation, reduced ejection fraction, and re-entrant/ectopic arrhythmia substrate — demonstrated clinically (echocardiography, ECG).
  9. This culminates in the clinical syndrome of congestive heart failure, ventricular arrhythmia, and — in a substantial subset — sudden cardiac death, sometimes as the presenting event (documented post-mortem via elevated pericardial-fluid NT-proBNP; PMC7476613, PMID:32939432).

Branch point (inferred, not fully demonstrated in humans): A parallel/contributing pathway proposes that certain missense or in-frame mutations act principally by destabilizing dystrophin's interaction with binding partners, notably neuronal nitric oxide synthase (nNOS) via the rod-domain spectrin repeats 16–17, rather than (or in addition to) abolishing DGC mechanical linkage outright — this would perturb nitric-oxide-dependent vascular and metabolic regulation in the myocardium. This mechanism is proposed in the literature (Franz et al., cited in PMC4491663) but is less directly demonstrated for the cardiac-selective phenotype than the isoform-compensation mechanism above, and should be treated as a secondary/candidate branch rather than an established parallel causal chain.

Molecular pathways and cellular processes

  • DGC/mechanotransduction signaling (GO:0007169-adjacent mechanosensitive pathways) — primary disrupted pathway.
  • Calcium-handling/excitation-contraction coupling — secondarily dysregulated (GO:0086001, cardiac muscle cell action potential; GO:0086036, regulation of cardiac muscle cell membrane potential are candidate GO terms).
  • Fibrotic remodeling response — cardiac fibroblast activation and extracellular matrix deposition following myocyte loss (a process the dismech KB models generically via the fibrotic_response module — relevant conforms_to target if curating this entry: e.g., a node such as "Cardiac Fibroblast Activation" conforming to fibrotic_response#Mesenchymal Cell Activation).
  • Apoptosis/necrosis — GO:0006915 (apoptotic process) and necrotic cell-death pathways downstream of calcium overload.
  • Nitric oxide signaling (nNOS-dystrophin axis) — candidate secondary pathway (GO:0006809, nitric oxide biosynthetic process).

Protein dysfunction

Loss of function (null) or destabilization (reduced half-life / disrupted binding-partner interactions) of the 427-kDa full-length dystrophin protein; UniProt P11532 (human DMD/dystrophin). No gain-of-function or dominant-negative mechanism is established for XLDCM specifically.

Cell types and biological processes (candidate CL/GO term suggestions for KB curation)

  • Cell types: cardiac muscle cell (CL:0000746), ventricular cardiac myocyte, cardiac fibroblast (CL:0002548).
  • Anatomical/subcellular: sarcolemma (GO:0042383, sarcolemma — Cellular Component), sarcoplasmic reticulum, mitochondrion (secondary calcium-overload target).

Molecular profiling and advanced technologies

No large-scale transcriptomic/proteomic/single-cell dataset specific to human XLDCM cardiac tissue was identified in this search — the rarity and lethality of the classic phenotype has historically limited access to fresh myocardial tissue for such profiling. Isoform-expression mapping (Neri et al. 2012) used targeted RT-PCR/immunohistochemistry on autopsy/explanted human ventricular tissue rather than genome-wide profiling. Human iPSC-derived cardiomyocyte (hiPSC-CM) models are an emerging platform for preclinical mechanistic and exon-skipping efficacy testing in dystrophin-deficient cardiomyocytes (cited in PMC4491663, referencing exon-51-skipping antisense oligonucleotide studies achieving ~30% wild-type dystrophin restoration in hiPSC-CMs).

7. Anatomical Structures Affected

  • Organ level: Heart (primary); specifically left ventricle (predominant chamber affected, particularly the posterobasal/inferolateral free wall). Skeletal muscle is spared or only mildly/subclinically involved by definition of the "pure" XLDCM phenotype (UBERON:0000948 heart; UBERON:0002084 heart left ventricle).
  • Secondary/complication-level organ involvement: lungs (pulmonary congestion from heart failure), liver (congestive hepatopathy), kidneys (cardiorenal syndrome) — standard heart-failure sequelae, not primary disease targets.
  • Body systems: Cardiovascular system primarily; the neuromuscular system is the "other" system implicated by the causal gene but is the spared system in this specific phenotype, which is the disease's defining clinical feature.
  • Tissue/cell level: Cardiac (striated) muscle tissue; ventricular cardiomyocytes as the principal affected cell population; cardiac fibroblasts secondarily activated in the fibrotic-replacement process; cardiac conduction system tissue (implicated in arrhythmia generation).
  • Subcellular level: Sarcolemma (site of primary DGC disruption), sarcoplasmic reticulum and mitochondria (secondary calcium-handling/energetic dysfunction), cytoskeleton (actin-dystrophin linkage).
  • Localization: Typically bilateral-chamber but LV-predominant; myocardial biopsy/CMR literature specifically flags the LV posterobasal wall as an early and characteristic site of fibrofatty replacement.

8. Temporal Development

  • Onset: Classic XLDCM manifests in adolescence/young adulthood (10–20 years) in hemizygous males; manifesting female carriers typically present later, in the 4th–5th decade. Some case reports describe onset as late as the 6th decade (a 50-year-old patient with normal CK, cited in PMC4491663). Onset pattern is generally insidious, with pre-symptomatic ECG or biomarker abnormalities often detectable before overt heart failure.
  • Progression: Rate is strongly genotype-dependent — the original Berko & Swift kindred showed rapid, lethal progression (death 5–12 months after symptom onset); a documented case showed cardiothoracic ratio increasing from 47% (age 12) to 71% (age 18) before death. In contrast, exon 45–55 hotspot deletions are associated with a more indolent course and better medication responsiveness. Overall course is progressive rather than relapsing-remitting, though rate of decline is highly variable by genotype.
  • Stages: Not formally staged with a disease-specific system; standard heart-failure staging (ACC/AHA Stage A–D, NYHA functional class) is applied clinically.
  • Remission: No spontaneous remission is described; pharmacologic stabilization of LV function (with ACE inhibitors/beta-blockers) can arrest or slow progression in some genotypes, but this is disease modification/stabilization rather than remission.
  • Critical periods: Early adolescence (for males) appears to be a key window for pre-symptomatic surveillance — standard dystrophinopathy cardiac-care guidelines recommend baseline cardiac evaluation by age 6 and annual evaluation from approximately age 10 onward, precisely because subclinical cardiac dysfunction can precede symptoms by years (see §10).

9. Inheritance and Population

Epidemiology

  • XLDCM as a narrowly defined "cardiac-only" entity is very rare, historically reported as individual pedigrees rather than population-based incidence/prevalence figures — no dedicated incidence/prevalence estimate for the isolated cardiac phenotype was located in this search.
  • Broader context: non-ischemic DCM overall has an estimated prevalence around 1 in 220 by cardiac MRI-based studies, with prevalence roughly twice as high in men as women, and asymptomatic idiopathic DCM prevalence potentially ≥1 in 250 (Nat Rev Cardiol epidemiology review).
  • Within cohorts of "idiopathic"/familial DCM screened for DMD mutations, the yield is 3–13.6% depending on population and case-ascertainment (Italy 6.5%, PMID:10841222; Japan 3%, PMID:15671604; a US pediatric cohort 13.6%, per PMC4491663) — indicating DMD mutations are a clinically meaningful, likely underrecognized, cause of pediatric and young-adult DCM presenting without overt skeletal myopathy.

Inheritance Pattern

X-linked, classically recessive at the population level but with frequent manifesting heterozygotes (carrier females) due to skewed X-inactivation — clinically this produces a pattern of early-onset disease in males and later-onset, generally milder (but not trivial) disease in obligate carrier females, with no male-to-male transmission (a key pedigree clue distinguishing X-linked from autosomal dominant DCM).

Penetrance and Expressivity

  • Penetrance in males: Essentially complete for cardiac disease by adulthood in classic XLDCM pedigrees, though age of onset and rate of progression are highly variable by mutation type.
  • Penetrance/expressivity in female carriers: Variable and X-inactivation-dependent — cardiomyopathy is common in DMD carriers (estimates from the broader dystrophinopathy-carrier literature suggest cardiac abnormalities in up to ~40s% of carriers screened by CMR/echo over time, though estimates vary by study and modality), and carrier cardiomyopathy may be the initial or only manifestation of the underlying mutation (PMC7397028, "Cardiac Involvement in Dystrophin-Deficient Females," Genes 2020, PMID cross-referenced via DOI:10.3390/genes11070765).
  • Genetic anticipation: Not a recognized feature of DMD-associated cardiomyopathy (unlike repeat-expansion disorders).
  • Germline mosaicism: Recognized generally in dystrophinopathy (relevant to recurrence-risk counseling for de novo cases) but not specifically quantified for the XLDCM subphenotype.
  • Founder effects / carrier frequency: No XLDCM-specific founder mutation was identified in this search; the exons 45–55 deletion hotspot is a recurrent, non-founder mutational hotspot common to dystrophinopathy generally (attributable to the region's susceptibility to Alu-mediated recombination), not a single population-specific founder allele.
  • Consanguinity: Not a relevant risk factor for an X-linked condition in the way it is for autosomal recessive disease (though it can increase homozygosity in rare affected females).

Population Demographics

  • Sex ratio: Overwhelmingly male-predominant for the classic, early/severe phenotype, consistent with X-linked inheritance; carrier females represent a distinct, later-onset risk group rather than an equally affected group.
  • Ethnic/geographic distribution: No specific ethnic or geographic enrichment for XLDCM was identified; DMD-mutation-attributable DCM has been documented across multiple studied populations (Italian, Japanese, American cohorts cited above), suggesting the phenomenon is not geographically restricted, though systematic global prevalence data are lacking.

10. Diagnostics

Clinical/Laboratory Tests

  • Creatine kinase (CK): Variably elevated (normal to markedly elevated, e.g., >2,500 IU/L); notably can be normal, especially with exon 45–55 hotspot deletions or in later-onset/female cases — CK is a supportive but non-discriminating test for XLDCM specifically (in contrast to its high sensitivity for classic DMD).
  • NT-proBNP: The best-validated serum biomarker for tracking systolic dysfunction and mortality risk in dystrophinopathy cardiomyopathy broadly; threshold >200 pg/mL for severe systolic dysfunction (90.5%/90.9% sensitivity/specificity) (Circ Heart Fail 2024).
  • Troponin I: Detects subclinical myocardial injury ("troponin leak") correlating with LGE on CMR, but is not well correlated with overall cardiomyopathy progression and should be interpreted cautiously, especially in the context of drug-toxicity monitoring in trials (PMID:34429516).

Imaging

  • Echocardiography: First-line, serial modality for LV size/function; shows LV enlargement, wall-motion abnormality, systolic/diastolic dysfunction.
  • Cardiac MRI (CMR): Recommended to be incorporated into surveillance by early adolescence; detects late gadolinium enhancement (LGE), the imaging correlate of the characteristic LV posterobasal/inferolateral fibrofatty replacement, often preceding overt systolic dysfunction on echo.

Electrophysiology

  • ECG: Characteristic (though not pathognomonic) findings — high R/S ratio (R/S >1) in right precordial leads (V1–V2), deep Q waves in lateral (I, aVL, V5–V6) or inferior leads, sinus tachycardia, shortened PR interval, and various arrhythmias (sinus arrhythmia, atrial/ventricular ectopy). These findings can precede symptomatic heart failure and are part of recommended baseline/surveillance evaluation.

Biopsy/Pathology

  • Skeletal muscle biopsy: In "pure" XLDCM, shows only mild myogenic changes (fiber-size variation, occasional necrosis, centronuclear fibers) despite normal strength; dystrophin immunostaining shows absence or reduction of dystrophin, confirming the molecular diagnosis even in the absence of clinical myopathy.
  • Myocardial biopsy (rarely performed given risk, more often assessed via CMR or at transplant/autopsy): replacement fibrosis/fatty infiltration, especially LV posterobasal wall; atrophic myocyte changes with loss of striation, vacuolation, and nuclear degeneration.

Genetic Testing

  • Multiplex ligation-dependent probe amplification (MLPA) or targeted deletion/duplication analysis of DMD is the recommended first-tier test given that ~65–70% of dystrophinopathy-causing mutations are deletions/duplications; sequencing (gene panel, exome, or genome) is needed to detect point mutations, small indels, and deep intronic/splice variants (e.g., the K18N, F3228L, D3368G missense variants and splice-site mutations described above).
  • Muscle-promoter/exon-1-specific analysis is particularly relevant when XLDCM is clinically suspected (cardiac-predominant phenotype with normal/near-normal strength), since standard multi-exon deletion panels can sometimes under-detect isolated promoter-region lesions if probe coverage is incomplete.
  • Family segregation studies / carrier testing: Central to counseling in this X-linked condition — once a proband's variant is identified, targeted testing of at-risk female relatives (mothers, sisters, maternal aunts) for carrier status and subsequent cardiac screening is standard practice.

Clinical Criteria / Differential Diagnosis

XLDCM should be distinguished from: - Classic DMD/BMD-associated cardiomyopathy (skeletal myopathy present and typically dominates the clinical picture). - Barth syndrome (TAZ/tafazzin, Xq28) — X-linked, presents in infancy/early childhood with DCM ± LV noncompaction, endocardial fibroelastosis, skeletal myopathy, neutropenia, growth delay, and 3-methylglutaconic aciduria; a metabolically and clinically distinct X-linked cardiomyopathy (see §14 for detail). - Danon disease (LAMP2, Xq24) — X-linked dominant lysosomal disorder; predominantly hypertrophic cardiomyopathy in males (dilated/hypertrophic mix in females), with Wolff-Parkinson-White pattern (68% of males, 27% of females), skeletal myopathy, and intellectual disability — mechanistically and phenotypically distinct from dystrophin-related XLDCM despite both being X-linked cardiomyopathies. - X-linked Emery-Dreifuss muscular dystrophy (EMD/emerin, Xq28) — joint contractures plus cardiac conduction defects/arrhythmia progressing to dilated cardiomyopathy; some EMD missense variants have been reported to cause isolated dilated cardiomyopathy without the classic EDMD triad (PMC12185710, 2025), making this an important differential/mimic for "isolated" X-linked DCM alongside dystrophin-related XLDCM. - Non-genetic causes of pediatric/young-adult DCM (myocarditis, etc.) should be excluded per standard DCM work-up.

Screening

No population-based newborn screening exists specifically for XLDCM (newborn CK-based screening programs for DMD exist in some regions/countries but are aimed at classic DMD, not the cardiac-only phenotype). Cascade/targeted screening of at-risk relatives once a family DMD variant is known — and routine cardiac screening of DMD/BMD carrier females — is the relevant applied screening paradigm (ACMG/genetic-counseling guidance for dystrophinopathy carriers recommends baseline and periodic cardiac evaluation).

11. Outcome/Prognosis

  • Survival: Highly genotype-dependent. In the original Berko & Swift kindred, affected males survived only 5–12 months from symptom onset, dying typically in their late teens/early 20s. In contrast, patients with exons 45–55 deletions have been reported to have relatively good life expectancy with appropriate heart-failure therapy. Comparative registry data on DMD- vs. BMD- vs. other-etiology DCM show 5-year survival after cardiomyopathy diagnosis of 57% in DMD, 100% in BMD, and 71% in other DCM etiologies (Pediatric Cardiomyopathy Registry, PMID:18513510) — though this compares classic DMD/BMD (with skeletal disease) rather than isolated XLDCM specifically, it is the best available comparative mortality benchmark in the DMD-cardiomyopathy space.
  • Cause of death: Progressive heart failure and/or lethal ventricular arrhythmia/sudden cardiac death; sudden death can occur without prior overt heart-failure symptoms (documented via elevated pericardial NT-proBNP at autopsy, PMID:32939432).
  • Heart transplantation outcomes: For dystrophinopathy-associated cardiomyopathy patients who reach transplant, survival is comparable to non-dystrophinopathy transplant recipients — 89% vs. 91% at 1 year and 83% vs. 78% at 5 years, with no significant difference in rejection, infection, or allograft vasculopathy rates (cited via ScienceDirect summary, "Clinical outcomes after cardiac transplantation in muscular dystrophy patients"). A more recent single-center case series reported 100% survival at median 16-month follow-up with good functional capacity, albeit with some postoperative respiratory/swallowing complications reflecting underlying neuromuscular comorbidity (PMID:28580208, "Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series").
  • Prognostic factors: Mutation location/type (5′ promoter-exon 1 mutations portend more severe cardiac-selective disease; exon 45–55 deletions portend milder, more treatable disease), degree of X-inactivation skewing in carrier females, presence and extent of LGE on CMR, and NT-proBNP level.
  • Morbidity: Progressive heart failure symptoms, arrhythmia burden (requiring, in some cases, ICD/pacemaker), and — in patients who also carry some skeletal-muscle involvement — additive neuromuscular disability; QOL burden is substantial given the often rapid, unpredictable course in the severe subtype.

12. Treatment

Pharmacotherapy (standard heart-failure therapy, first line)

  • ACE inhibitors (e.g., perindopril, lisinopril) — foundational therapy; NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to the specific agent.
  • Beta-blockers (e.g., bisoprolol) — combination ACE-inhibitor + beta-blocker therapy showed significant improvement in LV fractional shortening compared with ACE-inhibitor monotherapy in the dystrophinopathy-cardiomyopathy literature cited in PMC4491663.
  • Angiotensin receptor blockers (ARBs) (e.g., losartan) — a randomized double-blind trial of lisinopril vs. losartan in DMD cardiomyopathy showed both effective, without conclusively establishing superiority of one over the other (PMC3871420).
  • Mineralocorticoid receptor antagonists, diuretics, digoxin — standard adjuncts for symptomatic heart failure.
  • Prophylactic (pre-symptomatic) ACE-inhibitor/beta-blocker therapy: The DMD Heart Protection Study (randomized, placebo-controlled trial of perindopril + bisoprolol in boys with DMD aged 5–13 with normal LV function) found no significant difference in LV function between early/prophylactic and delayed treatment arms at 36 or 60 months of follow-up, raising an open question about whether prophylactic therapy confers meaningful benefit over prompt treatment once dysfunction is first detected (PMID:30573480 protocol; PMID:40130400 long-term follow-up, Eur J Neurol 2025). This is an important, recent (2025) nuance for clinical guidance — prophylactic therapy is not unambiguously superior to a "treat at first detected dysfunction" strategy in trial data, though the trial itself notes methodological limitations (small numbers, no untreated control arm at long-term follow-up, echo insensitivity).
  • Corticosteroids: Beneficial for skeletal and cardiac outcomes in classic DMD but not specifically recommended for the isolated XLDCM cardiac phenotype, per the PMC4491663 synthesis.

Advanced/Interventional Therapies

  • Cardiac resynchronization therapy / pacemakers: For ventricular dyssynchrony or conduction disease.
  • Implantable cardioverter-defibrillator: Relevant given the arrhythmia/sudden-death risk, though disease-specific ICD-outcome data for XLDCM specifically were not located in this search.
  • Partial left ventriculectomy (Batista procedure) and LV assist devices: Described as options in the dystrophinopathy cardiomyopathy literature for advanced/refractory disease.
  • Heart transplantation: The only curative option for end-stage dystrophinopathy-associated heart failure refractory to medical therapy; outcomes are comparable to non-dystrophinopathy transplant recipients (see §11), making transplant a reasonable option specifically in patients whose skeletal/pulmonary status (in "pure" XLDCM, typically preserved) does not preclude major surgery — an important point of differentiation from classic DMD, where respiratory/neuromuscular comorbidity often complicates transplant candidacy.

Experimental / Gene-Targeted Therapeutics (Duchenne/dystrophinopathy pipeline, cardiac-relevant)

  • Exon-skipping antisense oligonucleotides (e.g., eteplirsen [exon 51], golodirsen, viltolarsen, casimersen — FDA-approved for skeletal-muscle indications in eligible DMD genotypes) convert out-of-frame to in-frame mutations at the RNA level; cardiac delivery efficiency is a recognized limitation relative to skeletal muscle. hiPSC-cardiomyocyte studies show exon-51-skipping AOs can restore dystrophin to ~30% of wild-type levels in vitro (cited in PMC4491663).
  • AAV micro-dystrophin gene therapy: Multiple constructs in clinical development for DMD skeletal-muscle disease (e.g., fordadistrogene movaparvovec, delandistrogene moxeparvovec). Cardiac efficacy data are earlier-stage: a micro-dystrophin construct optimized for skeletal efficacy (AAV-μDys5) fully prevented cardiac pathology and preserved ejection fraction (>45%) through 18 months in a severe DMD mouse model (Fiona/dko), while some other microdystrophin constructs paradoxically accelerated cardiac disease, apparently via competition between micro-dystrophin and utrophin at the cardiomyocyte membrane — a significant, actively studied safety signal (PMC11382885, "Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy," 2024). Because DMD cardiomyopathy typically emerges in the teens while current gene-therapy trials are conducted in young boys, it will likely be a decade before human cardiac clinical outcomes from these gene therapies are known — an important caveat for current disease-modeling/treatment-planning purposes.
  • Membrane sealants (e.g., poloxamer 188): improved ventricular geometry in dystrophic mice and prevented cardiac injury/dilation in dystrophic dogs (Metzger et al., cited in PMC4491663) — a mechanistically distinct, membrane-stabilizing (rather than gene-restorative) therapeutic strategy.
  • AAV-microutrophin: Reported to confer durable cardioprotection against pharmacologic and exercise-induced injury in the mdx mouse (2025 preclinical study).

Treatment Algorithm / Strategy

Standard approach: (1) baseline and serial cardiac surveillance (§10) from diagnosis; (2) initiate ACE-inhibitor/ARB ± beta-blocker at first detection of LV dysfunction (with an open question, per the 2025 DMD Heart Protection Study follow-up, about whether earlier prophylactic initiation adds benefit over prompt treatment at first detected dysfunction); (3) escalate to standard advanced heart-failure therapies (MRA, device therapy) as needed; (4) consider transplantation for refractory end-stage disease, particularly favorable in "pure" XLDCM given typically preserved skeletal/respiratory status relative to classic DMD.

13. Prevention

  • Primary prevention: Not applicable in the classic sense for a monogenic disorder, other than reproductive genetic counseling — carrier testing of at-risk female relatives, prenatal diagnosis, and preimplantation genetic testing (PGT) are the relevant "primary prevention" tools once a familial DMD variant is identified.
  • Secondary prevention (early detection): Systematic cardiac screening of at-risk individuals — both males in families with known DMD mutations and, critically, female carriers, who are often clinically silent for skeletal disease but at meaningful risk of cardiomyopathy. Dystrophinopathy-specific guidelines (per GeneReviews/multidisciplinary cardiac-care consensus) recommend baseline cardiac evaluation (ECG + echo and/or CMR) at diagnosis or by age 6, with at least annual complete cardiac evaluation from ~age 10 in DMD (more frequent — every 6 months — once ventricular dysfunction is detected) and at least biennial evaluation from diagnosis in BMD; carrier females warrant baseline evaluation with periodic follow-up given their variable, X-inactivation-dependent risk (PMC9577913, "Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations").
  • Tertiary prevention: Early pharmacotherapy at first detection of LV dysfunction (§12) to slow progression and prevent complications (arrhythmia, sudden death, decompensated heart failure).
  • Genetic counseling: Central to management given X-linked inheritance — recurrence-risk counseling for carrier mothers, discussion of variable expressivity/manifesting-carrier risk, and cascade testing of at-risk relatives.
  • No immunization or infectious-prevention component is relevant, and no population-level public-health/environmental intervention applies, given the monogenic, non-infectious, non-environmentally-triggered etiology.

14. Other Species / Natural Disease

  • Taxonomy: Naturally occurring dystrophin-deficient cardiomyopathy is well documented in dogs (multiple breeds) and has been modeled in additional species below (NCBI Taxonomy: Canis lupus familiaris NCBITaxon:9615; Mus musculus NCBITaxon:10090).
  • Golden Retriever Muscular Dystrophy (GRMD): A naturally occurring, genetically homologous canine dystrophinopathy model. Cardiac phenotyping shows early ECG changes, elevated heart rate, reduced cardiac chamber size, disproportionately reduced myocardial mass, and — in older dogs — fatty infiltration and vascular hypertrophy correlating with lesion severity (biorxiv 2024, "Early Natural History of Cardiomyopathy and Cardiac Stress Response in Young Dogs with Golden Retriever Muscular Dystrophy"; PMC5438519, "The golden retriever model of Duchenne muscular dystrophy"). GRMD clinical severity (progressive gait impairment, dyspnea, dysphagia, delayed dilated cardiomyopathy) more closely parallels the progressive human DMD course than rodent models do, making it an important translational bridge (PMC5438519).
  • X-linked muscular dystrophy in Labrador Retrievers: A second, independently characterized canine dystrophinopathy strain with phenotypic and molecular characterization reported (PMC7412789).
  • Comparative biology: The dystrophin gene and DGC structure are highly conserved across mammals; the canine models in particular recapitulate both the skeletal and cardiac phenotype spectrum, supporting cross-species mechanistic inference for the human cardiac-selective (XLDCM) phenotype specifically, though most canine cardiac-phenotyping work characterizes the "typical" (skeletal + cardiac) dystrophinopathy course rather than an isolated cardiac-only canine analog of XLDCM.
  • Zoonotic potential: None — this is a non-infectious, inherited, non-transmissible disease; not applicable.

15. Model Organisms

Model Type Key cardiac-phenotype findings
mdx mouse Genetic (spontaneous dystrophin-null point mutation) Standard, most widely used DMD model; shows dilated cardiomyopathy with decreased fractional shortening and impaired fatty-acid metabolism, but cardiac dysfunction is milder and later-onset than in humans — young adult mdx mice do not show overt cardiac functional deficits, a recognized model limitation (PMC4348559, "Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy"). Aged female mdx mice are noted as a genetically and phenotypically closer match to human dystrophic cardiomyopathy than young male mice.
Cmah−/−;mdx (Cmah-deficient mdx) Enhanced genetic model (double knockout) Accelerated cardiac phenotype vs. standard mdx — earlier reduction in RV ejection fraction/stroke volume (by 12 weeks) and LV diastolic volume/stroke volume deficits (by 24 weeks) (PMID:30281092).
Fiona/dko (dystrophin/utrophin double-knockout background) Enhanced genetic model Severe DMD cardiomyopathy model used to test AAV-μDys5 microdystrophin gene therapy, which fully prevented cardiac pathology and preserved EF >45% through 18 months (PMC8119181, PMC9981810).
Dmdmdx rat Genetic (CRISPR-generated dystrophin-null rat) Proposed as a cardiovascular-phenotyping model potentially better suited than mice for capturing the human-like cardiovascular course (PMC7927653, "Cardiovascular phenotype of the Dmdmdx rat").
GRMD / Labrador X-linked muscular dystrophy dogs Naturally occurring large-animal model See §14 — closest large-animal phenocopy of human dystrophinopathy cardiomyopathy progression; used for AAV/gene-therapy and membrane-sealant (poloxamer 188) preclinical efficacy testing.
Human iPSC-derived cardiomyocytes (hiPSC-CMs) In vitro/cellular model Emerging platform for mechanistic study and exon-skipping/AAV efficacy testing directly in dystrophin-deficient human cardiomyocytes; exon-51-skipping AOs restored dystrophin to ~30% of wild-type in this system (cited in PMC4491663).
Tafazzin (Taz) knockdown mouse (Barth syndrome model, distinct X-linked cardiomyopathy gene, included for comparative context) Genetic knockdown Recapitulates hypertrophic-cardiomyopathy-like features of Barth syndrome; used in a 2025 study testing whether pharmacological ketone elevation could alleviate the cardiomyopathy — it did not alleviate the phenotype, an informative negative preclinical result (PMC12711585).

Model limitations (general, relevant to XLDCM translational work)

Standard mouse models substantially under-recapitulate the severity and tempo of human dystrophinopathy cardiomyopathy, necessitating enhanced genetic backgrounds (Cmah-null, dystrophin/utrophin double-knockout) or large-animal (canine) models for therapies intended to translate to the human cardiac phenotype. No model organism was identified in this search that specifically and selectively recapitulates the "cardiac-only" (skeletal-sparing) XLDCM phenotype as opposed to the combined skeletal-plus-cardiac phenotype typical of DMD/BMD models — this is a notable translational gap: the isoform-compensation mechanism thought to underlie human XLDCM's tissue selectivity (§6) has not, per this search, been specifically reproduced and validated as a standalone cardiac-selective model.

Key Differential/Related X-linked Cardiomyopathy Genes (Summary Table)

Gene (locus) Disorder Cardiac phenotype Distinguishing extracardiac features
DMD (Xp21.2-p21.1) XLDCM / dystrophinopathy cardiomyopathy Dilated CM, ventricular arrhythmia Skeletal myopathy absent/minimal (XLDCM) to severe (DMD/BMD)
TAZ (Xq28) Barth syndrome DCM ± LV noncompaction, endocardial fibroelastosis, HCM variants; onset typically infancy/first year of life Skeletal myopathy, neutropenia, growth delay, 3-methylglutaconic aciduria
LAMP2 (Xq24) Danon disease Predominantly hypertrophic CM (males); mixed HCM/DCM (females); WPW pattern Skeletal myopathy, intellectual disability, glycogen accumulation
EMD (Xq28) Emery-Dreifuss muscular dystrophy 1 / isolated DCM Conduction disease progressing to DCM; some variants cause isolated DCM without classic EDMD triad Joint contractures, humero-peroneal weakness (classic EDMD1); can be absent in isolated-DCM EMD variants

Notes on Evidence Gaps and Confidence

  • The classic "XLDCM" literature is largely composed of historical pedigree studies (1987–1990s) supplemented by more recent mechanistic (isoform-expression) and case-report/case-series work; large modern epidemiological or multi-omic datasets specific to the isolated cardiac phenotype are sparse. Statements about frequency (e.g., "3–13.6% of DCM cohorts") reflect DMD-mutation yield in general DCM screening cohorts, not the narrower "pure" XLDCM phenotype specifically, and should be flagged as such in any KB curation.
  • MONDO ID mapping for this specific entity was not confirmed in this session (OMIM #302045 was located, but a direct MONDO cross-reference lookup was not performed) — verify before use in structured curation.
  • The 2025 DMD Heart Protection Study long-term follow-up (PMID:40130400) is a genuinely recent, clinically important update: it tempers earlier assumptions that prophylactic ACE-inhibitor/beta-blocker therapy is unambiguously superior to treatment initiated at first detected dysfunction — this should be represented with appropriate caveats given it is a single (if well-designed) trial with acknowledged methodological limitations.
  • The 2024 microdystrophin gene-therapy cardiac-safety signal (PMC11382885 — some constructs accelerating cardiac disease via microdystrophin/utrophin membrane competition) is an important, very recent (2024) caveat for the gene-therapy pipeline's cardiac relevance and should not be omitted when discussing gene therapy as a treatment prospect for dystrophinopathy cardiomyopathy generally, including XLDCM.

Sources